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Cholesterol is crucial for mammalian survival by playing important 
roles, such as regulating membrane fluidity and as a precursor for the 
synthesis of steroid and sex hormones, bile acids, and Vitamin D.  In 
addition, cellular and organismal regulation of cholesterol is important for 
health.  For example, increased levels of plasma LDL cholesterol are a risk 
factor for coronary heart disease and stroke.  Intracellular cholesterol levels 
are regulated by a variety of mechanisms, but numerous studies indicate a 
very important role for transcriptional regulation by Sterol Regulatory 
Binding Proteins (SREBPs), Liver X Receptors (LXRs) and Unfolded 
Protein Response (UPR) or ER stress families of transcription factors.  
StARD4 is regulated by SREBPs and we have chosen to make a mouse 
knockout model to characterize its role in-vivo. 
StARD4, expressed primarily in liver and macrophages, is a known 
intracellular cholesterol transporter previously shown to be down-regulated 
~2 fold in liver, by high cholesterol feeding.  It is thought to be involved in 
the dynamics of cholesterol movement between ER, plasma membrane, 
endosomes and lipid droplets.  Based on these observations, I hypothesized 
that a knockout of StARD4 in a mouse model would show altered 
intracellular cholesterol sorting, and figuring out the basis of such a defect 
would provide insight into the general mechanisms of intracellular sterol 
transport.  To my surprise, StARD4 knockouts were viable and for the most 
part phenotypically normal.  They showed no alteration in plasma or liver 
cholesterol or triglycerides.  In addition, no abnormalities were found in 
glucose metabolism, macrophage cholesterol efflux, or atherosclerosis 
susceptibility.  Based on these observations, I hypothesize that in-vivo, the 
absence of StARD4 is compensated for by other genes and/or pathways.  In 
the future, it will be necessary to identify these compensatory 
mechanism(s) to truly understand the physiological role of StARD4. 
I also studied another aspect of cholesterol metabolism related to its 
transport in plasma in high density lipoproteins (HDLs).  HDL is involved 
in the reverse cholesterol transport mechanism, whereby excess cholesterol 
is removed from peripheral tissues and transported to the liver for 
excretion.  The major protein of HDL is apoA-I and in mouse models it has 
been shown that animals transgenic for apoA-I have increased HDL levels.  
This suggests increased apoA-I transcription as a mechanism for increasing 
HDL, which might be preventive or therapeutic for coronary heart disease.  
With this as a goal, as part of my thesis I studied the epigenetic regulation 
of apoA-I transcription.  I found that increased apoA-I transcription in liver 
cell culture cell lines was associated with highly unmethylated CpGs in the 
apoA-I promoter, and the reverse, in cultures with poor apoA-I expression.  
I also found histone marks associated with apoA-I expression.  This project 
was discontinued in favor of the StARD4 knockout mouse project.  
However, it might be continued in the future to reveal drug targets that alter 
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Chapter 1: Introduction 
 
Cholesterol’s Physiological Importance  
Cholesterol, the most abundant sterol in the human body, is essential 
for life, as its precursors and metabolites are involved in various cellular 
signaling events and cell functions (Soccio and Breslow 2004).  
Systemically, cholesterol is made available to mammals from dietary 
sources and eventual uptake from plasma lipoproteins (Goldstein and 
Brown 2009) and from de novo synthesis from acetyl-CoA using 20-30 
enzymes and cofactors (Bloch 1975).  However, its excess, especially high 
plasma levels of LDL-C (or commonely referred to as, “bad cholesterol”), 
is toxic and contributes to several diseases (Soccio and Breslow 2004).  
Most notably are atherosclerosis and stroke, accounting for nearly a million 
American deaths each year (Tabas 2002).  Therefore, it is critical that the 
body maintain appropriate cholesterol homeostasis, and understanding the 
mechanisms involved is important for developing new remedies for 
disorders of cholesterol metabolism. 
Cholesterol is a 27-carbon molecule that is rigid, planar, 
amphipathic, composed of a four ring steroid nucleus, a polar hydroxyl 
group and an alkyl side chain.  Cholesterol provides rigidity and structure 
to the plasma membrane, retaining membrane permeability and playing an 
important role in lipid rafts composition; structures that serve as scaffolds 
for various cell signaling pathways (van Meer, Voelker et al. 2008).  
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Cholesterol covalently interacts with and modifies other proteins, perhaps 
best exemplified by its role in regulation of sonic hedgehog, a major player 
in normal human development (Tabas 2002).  As a precursor of the steroid 
and stress hormones, notably the adrenal hormones, corticosterone, cortisol 
and aldosterone and the gonadal hormones progesterone, estradiol and 
testosterone, cholesterol plays a vital role in developmental/reproductive 
biology, as well as in stress response (Payne and Hales 2004).  
Additionally, cholesterol is a precursor for bile acids, which play varied and 
important physiological roles.  First, they are essential for absorption of 
lipids and all other fat soluble nutrients in the gut. Second, they are 
responsible for activation of signaling pathways, like the FXR nuclear 
hormone pathway, that regulates triglyceride, cholesterol, energy and 
glucose homeostasis (Thomas, Pellicciari et al. 2008).  Finally, cholesterol 
is the building block for vitamin D3 (or cholecalciferol), which is essential 




Figure 1.1 - Structural Composition of a Cholesterol Molecule 
 Cholesterol plays an extremely important role in the body and its 
level must be carefully regulated.  This includes tight regulation of the 
pathways for synthesis, as well as cellular influx and efflux.  Pathways exist 
to deal with excess cellular cholesterol, for example the repression of 
endogenous synthesis, esterification of cholesterol by the enzyme acyl-
coenzyme A:cholesterol acyltransferase (ACAT) and the ultimate efflux out 
of the cell as part of the reverse cholesterol transport (RCT) pathway 
(Tabas 2002).  However, upon failure, this excess can lead to the 
development of atherosclerotic plaques, which occur when excess 
cholesterol, carried in lipoproteins, settles in the subendothelial space of the 
vasculature.  The excess cholesterol in turn signals for the infiltration of 
monocytes which transform into foam cells that eventually undergo 
necrosis.  When foam cells necrose, vascular smooth muscle cells migrate 
into the space and form a cap.  Eventually, the build up of the plaque 
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induces inflammatory and apoptotic pathways that lead to plaque rupture.  
Rupture then leads to an acute thrombotic vascular infarction of that tissue 
which is the pathogenic cause of myocardial infarctions and thrombotic 
stroke (Hansson 2005).   Finally, due to its important role in bile synthesis, 
excess cholesterol can lead to the development of gallstones, which force 
over half a million Americans per year to undergo cholecystectomy 
(removal of the gallbladder) (Portincasa, Moschetta et al. 2006).  
Cholesterol de novo Synthesis and Dietary Uptake 
 There are two mechanisms by which the body acquires cholesterol; 
de novo synthesis and dietary intake.  About 1 gram of cholesterol is 
synthesized per day versus 300-500mg absorbed from the diet (Ikonen 
2006).  Cholesterol in ingested food is emulsified by bile acids, absorbed 
into intestinal epithelial cells and packaged into chylomicrons.  The latter 
enter the lymphatics from which they drain into the venous system and 
become plasma lipoproteins. 
Cholesterol synthesis occurs in all organs.  The cellular signaling 
pathway controlling cholesterol synthesis, commonly referred to as the 
HMG-CoA Reductase pathway, has been extensively researched for over 
20 years as it is the target of a blockbuster pharmaceutical therapy (Tobert 
2003).  Briefly, Acetyl-CoA, the metabolic product of glycolysis and fatty 
acid oxidation, is converted by 20-30 enzymes to four key intermediates, 
mevalonate, farnesyl pyrophosphate, squalene and lanosterol and then 
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ultimately to cholesterol. (Goldstein, DeBose-Boyd et al. 2006).  The 
pharmaceutical drug class of statins inhibit one of these enzymes called 
HMG-CoA Reductase, the rate limiting step in the production of 
mevalonate and ultimately cholesterol (Tobert 2003).    
 
Figure 1.2 - Brief Overview of the HMG-CoA Reductase pathway 
The diagram represents the HMG-CoA Reductase pathway for cholesterol synthesis 
and some of the other effected products, like Ras and Rho, by pathway intermediates 
which play important roles in cell proliferation, differentiation and migration.  Some 
of the anti-inflammatory responses of statins have been attributed to off-target effects 
on these proteins (Menge, Hartung et al. 2005). 
 
The complexity of cholesterol metabolism requires a controlling 
entity to balance overall cholesterol homeostasis and this burden falls 
primarily on the liver.  To this end, the liver balances the rate of synthesis 
and storage (in the form of cholesterol esters in lipid droplets or free 
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cholesterol in the plasma membrane), with the rate of efflux (both into the 
blood stream in lipoproteins and out of the body through the bile excretion 
pathways) and rate of influx (from the bloodstream) (Ikonen 2006). 
Lipoprotein Transport of Cholesterol in the Blood 
 Cholesterol and cholesterol esters are shuttled throughout the plasma 
in particles called lipoproteins.  The non-polar cholesterol esters and 
triglycerides in the core of the lipoprotein are solublized by 
apolipoproteins, while phospholipids and free cholesterol remain on the 
surface (Gotto, Pownall et al. 1986).   The transport of these lipoproteins 
resembles a circular pathway.  From the intestine, chylomicrons, 
triglyceride rich and containing apolipoprotein B-48 (ApoB48), are 
secreted.  Within the plasma, chylomicrons are metabolized into 
chylomicron remnants and undergo receptor mediated endocytosis by the 
liver (Redgrave 2004).  The liver secretes another triglyceride rich particle 
called very low density lipoprotein (VLDL), that contains additional 
apolipoproteins, ApoE and varied ApoC particles as well as ApoB100 
(Chang, Chang et al. 2006).  As VLDL makes it way through the 
vasculature, it is converted to IDL (intermediate density lipoprotein) via the 
action of a lipoprotein lipase (LPL) and then to LDL (low density 
lipoprotein).  At this stage, LDL has also lost ApoE and the ApoCs 
lipoproteins (Chang, Chang et al. 2006).  The last major lipoprotein, HDL 
(high density lipoprotein), or commenly referred to as, “good cholesterol,” 
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is produced as an ApoA-I containing discoidal particle in the liver and 
intestine.  Upon secretion into plasma, HDL begins its journey to maturity, 
evolving as it acquires free cholesterol from peripheral cells (Krieger 1999).   
Free cholesterol in discoidal HDL is esterified by LCAT in plasma, 
changing the shape of the particle to spherical with cholesterol ester in the 
center.  Both LDL and HDL are ultimately taken up in the liver by the LDL 
receptor (LDLR) and by scavenger receptor B1 (SRBI), respectively 
(Krieger 1999).  A more comprehensive coverage of the HDL particle and 









Figure 1.3 - Lipoprotein Metabolism 
The intestine absorbs dietary fat and packages it into chylomicrons, which are 
transported to peripheral tissues through the blood.  In muscle and adipose tissue, 
lipoprotein lipase breaks down the particles and the fatty acid component enters these 
tissues.  The subsequent remnant is taken up by the liver.  The liver then creates 
ApoB particles and enriches them with lipid particles to create VLDL, which is 
subsequently excreted into the plasma.  Lipolysis of this particle by lipoprotein lipase 
ultimately creates LDL which can be recycled to the liver by the LDL receptor.  The 
other component of this pathway is HDL.  Produced by both the intestine and liver as 
a lipid free ApoA-I particle, HDL is formed in a multi-step process.  Starting when 
ApoA-I recruits cholesterol from peripheral tissues via the ABCA1 transporter, the 
particle matures, collects more cholesterol from peripheral tissues via the ABCG1 
transporter and then ultimately converts to a mature HDL particle as its free 
cholesterol is esterified to cholesterol ester by lecithin cholesterol acyltransferase 
(LCAT).  Finally, HDL’s cholesterol is taken up by the liver by way of the SR-BI 
receptor or by transfer to LDL and VLDL by the cholesterol ester transfer protein 
(CETP) (Rader and Daugherty 2008). 
 
Studying Cholesterol Metabolism and Atherosclerosis in a Mouse 
Model 
 Mus musculus, commonly known as the laboratory mouse, is 
currently the most used animal model for studying atherosclerosis and its 
underlying pathways.  This was not always the case, as there are major 
phenotypic differences between humans and mice that make studying 
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atherosclerosis in mice challenging.  Notably, there are significant 
differences, both quantitatively and qualitatively, in cholesterol turnover 
between mice and humans (Dietschy and Turley 2002).  First, LDL tends to 
be cleared at a much higher rate in mice versus humans and thus mice tend 
to have higher HDL versus LDL and VLDL, when compared to humans.   
This is considered to be anti-atherogenic as VLDL and LDL are considered 
to be the problematic apolipoproteins in regard to development of 
atherosclerosis and as such makes mice a more difficult model for studying 
the progression of cardiovascular disease (Ikonen 2006).  Second, 
differences in lipoprotein composition and size in species of humans and 
mice has also been shown to effect the rate of atherosclerotic development 
(Veniant, Withycombe et al. 2001).  Third, mouse livers can edit ApoB100 
mRNA to produce and secrete ApoB48 labelled particles, a process only 
done in intestines in humans.  Fourth, mice can degrade dietary cholesterol 
via LXR (discussed in subsequent chapters), a process humans cannot do 
due to promoter differences in the downstream LXR gene, Cyp7A1.  
Finally, mice do not express CETP (discussed in subsequent chapters).  
Therefore, researchers, through dietary or genetic manipulation, have 
realized ways to manipulate mouse baseline lipid levels to push the system 
to be pro-atherogenic.   
The most common way to do this, is by knockout of the LDLR or 
ApoE genes (Ikonen 2006).   Both genes are involved in lipoprotein 
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clearance as LDLR-/- affects LDL clearance and ApoE-/- affects remnant 
clearance.  LDLR, expressed throughout the body, is the receptor for LDL.  
ApoE is a ligand found on both chylomicrons and VLDL and is involved in 
each particle’s clearance from plasma.  A study by Dansky et al  further 
delineated that the C57Bl6 mouse strain is a more sensitive strain to the 
progression of atherosclerosis, then the FVB mouse line (Dansky, Charlton 
et al. 1999; Teupser, Tan et al. 2006).  With this background in mind, one 
of the major aims of this thesis was the development of a C57Bl6 mouse 
knockout model of a gene called StARD4.  StARD4 is an intracellular 
cholesterol transporter whose knockout, will hopefully shed insight on 
pathways and mechanisms that control cholesterol’s fate intracellularly.  
The details behind the discovery and background for the StARD4 gene will 
be covered extensively in following sections. 
The HDL Lipoprotein 
Cholesterol is the main component of an HDL particle and there is 
an inverse correlation between atherosclerosis and plasma HDL levels 
cholesterol (Rader and Daugherty 2008).  First identified in studies using 
ultracentrifugation to separate lipoproteins by density, HDL has evolved 
into one of the risk factors analyzed to assess overall cardiovascular risk by 
clinicians (Rader 2006).  The most popular mechanistic explanation for 
HDL’s anti-atherogenic role is its involvement in what has been termed 
reverse cholesterol transport (RCT).  First proposed by Glomset et al in 
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1968, RCT encompasses a mechanism by which HDL facilitates the uptake 
of peripheral cholesterol and then carries this cholesterol to the liver for 
excretion into the bile (Glomset 1968).   Furthermore,  HDL’s function has 
been expanded by in-vitro work to include anti-inflammatory, antioxidant, 
anti-thrombotic (Barter, Nicholls et al. 2004) and nitric oxide-inducing 
mechanisms (Mineo, Deguchi et al. 2006).  For these reasons, HDL 
remains an attractive and highly researched lipoprotein for the development 
of novel therapeutics against atherosclerosis.    
HDL Components: ApoA-I & ApoA-II 
 The biosynthesis of an HDL particle is complex.   In plasma, nascent 
HDL consisting of ApoA-I phospholipid discs, attracts excess free 
cholesterol from membranes and HDL free cholesterol is esterified by the 
plasma enzyme LCAT.  This changes the shape of the HDL particle to 
spherical with a core of cholesterol ester and a surface of ApoA-I (some 
particles also have ApoA-II) and phospholipids (Rader 2006).  ApoA-I 
comprises the majority of the protein in a HDL particle, approximately 70% 
(Lewis and Rader 2005).  It was shown in the Breslow laboratory by Andy 
Plump, that ApoA-I knockout mice have low levels of HDL (Plump, 
Azrolan et al. 1997).  Furthermore, on a pro-atherogenic, ApoE -/- 
background, a human ApoA-I transgene was able to increase HDL and 
suppress atherosclerosis (Plump, Scott et al. 1994).   Therefore, 
upregulation of endogenous ApoA-I has remained an attractive target for 
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the development of therapeutics to raise HDL.  Only recently, has a small 
molecules advanced up unto phase II clinical trials to raise HDL levels via 
ApoA-I alterations (Resverlogix – RVX-208) and scientific research into 
the transcriptional regulation of ApoA-I remains an active area of research 
for the development of therapeutics against atherosclerosis.  The other 
major component of HDL, ApoA-II, plays a bit more confounding role in 
HDL metabolism.    Although only constituting about 20% of the HDL 
protein, its deletion in mice still leads to markedly decreased HDL levels; 
on the order of 60% lower (Weng and Breslow 1996).   However, oddly 
enough, over-expression of ApoA-II raises HDL, but also increases 
atherosclerosis (Warden, Hedrick et al. 1993).  This makes ApoA-II a more 
confusing target for study.   
Lipid Acquisition and Particle Maturation 
 Newly secreted HDL must acquire phospholipids and cholesterol in 
order to mature.  The first step in this process is lipidation of ApoA-I 
through the ABCA1 cholesterol pump found in peripheral tissues (Rader 
2006).  Genetic precedent for the importance of ABCA1 comes from 
Tangiers disease, whose genetic basis is a lack of ABCA1 and whose 
physiological phenotype includes low levels of HDL and ApoA-I as well as 
yellowed tonsils hepto-splenomegally due to cholesterol laden 
macrophages (Bodzioch, Orso et al. 1999).   ABCAI knockout mice have 
phenotypes similar to patients with Tangier disease (McNeish, Aiello et al. 
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2000).  Although ABCA1 is ubiquitously expressed, it seems that the 
majority of the lipidation of the nascent ApoA-I particle by ABCA1 takes 
place in the liver and intestines.   While nascent particles acquire free 
cholesterol via ABCA1, more mature HDL particles use a different 
cholesterol pump, ABCG1 and there is evidence that other uncharacterized 
pathways, such as the role of SR-B1in reorganizing plasma membrane 
cholesterol, direct contact or limited diffusion might play a role in HDL 
particle maturation (Yancey, de la Llera-Moya et al. 2000; Rader 2006).   
 It is estimated that in mice, over 90 mg of cholesterol per kilogram 
of body weight is effluxed daily from extrahepatic tissues to the HDL 
particle (Dietschy and Turley 2002).  However, the exact mechanism 
behind the lipidation of HDL particles remains a highly researched area.  
What is evident is that all extrahepatic cells require cholesterol, some of 
which can’t be metabolized and thus the tissues require a mechanism for 
the efflux of cholesterol to occur.  Thus from this basic understanding, it 
seems that large tissues such as skeletal muscle, adipose tissue and the skin 
would play large roles in contributing to the HDL particle (Rader 2006).   
This has been shown in vitro, as all of these cells lines have been shown to 
efflux cholesterol to ApoA-I and HDL particles.   
 Two other proteins that play a large role in the development of the 
HDL particle are phospolipid transfer protein (PLTP) and 
lecithin:cholesterol acyltransferase (LCAT).   PLTP helps the HDL particle 
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acquire phospholipids from triglyceride rich particles; VLDL & LDL 
(Huuskonen, Olkkonen et al. 2001).    LCAT, is responsible for 
esterification of cholesterol to cholesterol ester in the hydrophobic lipid 
core of the HDL particle.  LCAT probably acts on surface cholesterol 
which upon esterification becomes the much more hydrophobic cholesterol 
ester.  This changes the shape of the particle with the cholesterol ester 
migrating spontaneously into the core of a spherical particle.  Mouse 
models that knockout either gene, result in reductions in plasma HDL 
levels.  Thus enhanced expression of these 2 genes are legitimate targets for 
novel HDL raising therapies (Rietra, Slaterus et al. 1978) (Kuivenhoven, 
Pritchard et al. 1997).   
HDL Catabolism: SR-BI & CETP 
 The major site for uptake of the HDL particle is the liver.  The best 
described mechanism for this process is mediated by the scavenger receptor 
class BI (SR-BI).  SR-BI is responsible for what has been termed selective 
uptake; the uptake of HDL esterified cholesterol, without subsequent 
degradation of the HDL particle itself (Trigatti, Rigotti et al. 2000; Rader 
2006).   Interestingly and in accordance with SR-BI’s hypothesized role as 
an overall regulator of RCT, mouse knockouts of SR-BI show increased 
HDL levels and over-expression mouse models show a reduction in HDL 
levels (Zhang, Da Silva et al. 2005).  Furthermore, mouse studies of hepatic 
over-expression of SR –BI on atherosclerotic backgrounds show a 
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reduction in HDL levels with a concomitant reduction in atherosclerosis 
(Ueda, Gong et al. 2000).  However, to date there is very little direct 
evidence in humans for the role of SR-BI and HDL in atherosclerosis.  No 
SR-BI deficient patients have so far been reported and there are but a few 
genetic polymorphisms of the SR-BI gene (SCARBI) which in general have 
not been shown to be associated with HDL levels (Osgood, Corella et al. 
2003).   
 An alterative pathway for HDL catabolism is mediated by the 
cholesterol ester transfer protein (CETP). CETP’s role is to transfer 
triglycerides from apoB-containing lipoproteins and exchange them with 
cholesterol esters from the HDL particle (Rader 2006; Tall 2007).   Humans 
genetically deficient in CETP, were discovered in Japan and have 
extremely high levels of HDL cholesterol and reduced ApoA-I catabolism 
(Brown, Inazu et al. 1989).   In cholesterol ester turnover studies in 
humans, the majority of the excreted biliary cholesterol was first found to 
be transferred to apoB-containing lipoproteins, presumably by CETP 
(Schwartz, VandenBroek et al. 2004).  For these reasons, inhibiting CETP 
in humans became an attractive target for drug development, and one such 
inhibitor, Torcetripib, has been tested in clinical trials.  As hypothesized, 
Torcetripib increased HDL cholesterol levels by 50%, but unfortunately 
also increased the incidence of myocardial infarctions comparable to 
placebo (Clark, Sutfin et al. 2004).   These results may have been 
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confounded by off-target effects of the drug, such as raising blood pressure, 
but also raise the possibility that inhibition of CETP may have impeded 
reverse cholesterol transport and this mechanism might have been 
detrimental.    
A better mechanism for raising HDL cholesterol levels would be to 
increase the synthesis of its principal apolipoprotein ApoA-I.  This would 
both increase the favorable effects of HDL on the vasculature and increase 
reverse cholesterol transport. A worthy goal would be to mimic the increase 
of ApoA-I production in transgenics due to copy number, by developing a 
method to increase ApoA-I production pharmacologically.   
Transcriptional Control of ApoA-I 
One method of increasing plasma ApoA-I and HDL cholesterol 
levels would be to increase ApoA-I synthesis in liver and/or intestine.  This 
could be done via increased ApoA-I gene transcription and many studies 
have appeared in the last ~20 years on the cis- and trans- elements that 
regulate ApoA-I transcription.  The human ApoA-I gene is located at 
chromosome 11q23 at 116 MB.  It is in a complex with three other 
apolipoprotein genes from proximal to distal; ApoA-I, ApoC-III, ApoA-IV 
and ApoA-V (Malik 2003).   The ApoC-III gene is in the opposite 
orientation of the ApoA-I and ApoA-IV genes (Malik 2003).  Each of these 
genes has its own liver regulatory element in the proximal promoter, but 
there appears to be a single intestinal enhancer for all three genes at ~ 
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550bp up-stream of the ApoC-III start site.   For the ApoA-I gene many 
studies have shown the proximal promoter liver regulatory element to be 
between 220-110bps from the start of transcription (Ginsburg, Ozer et al. 
1995).  Multiple transcription factors have been shown to bind to different 
regions within this cis-element.  Mutational analysis has revealed that 
maximal ApoA-I liver expression depends on the integrity of the whole 
region, suggesting a level of interaction between transcription factors.  
Examples of transcription factors that play some role in regulation of 
ApoA-I are shown in figure 1.4.  Of these, HNF-4α appears to be the most 
important in maintaining hepatocyte expression (HNF-4 is also enriched in 
intestine) (Malik 2003).   In mice with hnf4-/-, developed using tetraploid 
embryo complementation (hnf4-/- are embryonic lethal) to allow for normal 
fetal liver development, the hnf4-/- livers have abolished ApoA-I expression 
(Li, Ning et al. 2000).  Additionally, expression of ApoA-I in hepatic and 
intestinal cell cultures was greatly diminished when the cells were 
transfected with an expression vector encoding a dominant-negative HNF-4 
(Fraser, Keller et al. 1997).  Although not with the consistency of HNF-4, 
some data suggest the proximal promoter region -220 to -110 also binds 
FoxA/HNF-3 (see diagram of the -220 to -110 region in figure 1.4).  How 
FoxA/HNF-3 and HNF-4 might interact is not clear.  Interestingly, the three 
dimensional structure of FoxA/HNF-3 resembles a globular domain of the 
linker histone H5. This suggests that FoxA/HNF3 might affect ApoA-I 
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transcription by interacting with a nucleasome binding domain, thereby 
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Figure 1.4 - ApoA-I Transcription Cluster & Associated Transcription Factors 
A pictorial representation of the ApoA-I/ApoC-III/ApoAIV gene cluster and their 
associated promoter/enhancer elements.  All three genes share an intestinal element, 
while each has a unique liver promoter region.  B)  An enlarged image of region -220 
to -110 with all reported associated transcription factor binding sites.  The most 











Epigenetics is a term that defines all meiotically and mitotically 
heritable changes in gene expression that are not coded in the DNA 
sequence itself (Egger, Liang et al. 2004).  These modifications can take 
place on the DNA sequenece itself or on the protein elements that package 
DNA into chromasomes. These proteins are called histones and they 
package and wind the DNA such that the DNA forms a spool around the 
histone proteins to compact the DNA sequence into chromatin and 
eventually chromosomes.   Three systems, DNA methylation, histone 
modification and RNA silencing are the most common forms of epigenetic 
regulation.  A perturbation in any one of these systems can lead to 
inappropriate or novel expression/silencing of genes and produce distinct 
phenotypes.  The possible implications of this are broad for the 
development of treatments involving activation of beneficial genes or 
silencing of harmful ones.  This is currently receiving great attention in the 
cancer field, notably in attempts to activate or reactivate tumor suppressor 
genes (Hong, Moorefield et al. 2007).  Epigenetics is a relatively nascent 
field and it has yet to be comprehensively applied to other diseases, 
including atherosclerosis.  In this regard, I thought an interesting potential 
thesis project would be to examine the epigenetic regulation of ApoA-I. 
The only literature on the epigenetic regulation of ApoA-I is a series 
of papers published between 1989 and 1991 performed by the Razin group 
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in Israel in collaboration with the Breslow laboratory at Rockefeller 
University  (Shemer, Eisenberg et al. 1991) (Shemer, Kafri et al. 1991) 
(Shemer, Walsh et al. 1990).  These papers used methylation-specific 
restriction enzymes, the only technique available at the time, to study DNA 
methylation of the ApoA-I gene in various tissues of C57BL/6J mice and 
relate the patterns observed to whether or not the gene was actually 
expressed.   They showed that in expressing tissues, like liver and intestine, 
the ApoA-I proximal promoter region was unmethylated, whereas in non-
expressing tissues like kidney, sperm and leukocytes this region was 
methylated (Shemer, Walsh et al. 1990).    In contrast, in all tissues the 3’-
end of the ApoA-I gene was hypomethylated, except for intestine where it 
was partially methylated (Shemer, Eisenberg et al. 1991).   Furthermore, in 
a mouse model expressing the human ApoA-I transgene only in the liver, 
but not any other tissue, hypomethylation of the human ApoA-I proximal 
promoter region was limited to liver with full methylation in other tissues 
including the intestine.  Interestingly, the neighboring genes CIII and A-IV 
also show DNA-methylation patterns that correspond with expression 
(Shemer, Eisenberg et al. 1991).   ApoC-III is expressed primarily in the 
liver and ApoA-IV in the intestine. Accordingly, the 5’ promoter region of 
ApoC-III is demethylated in the liver, whereas, the 5’ promoter region of 
ApoA-IV is demethylated in the intestine.  In summary, for the adjacent 
ApoA-I, C-III, A-IV genes, promoter DNA demethylation corresponded to 
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high expression and partial or full methylation to low or background 
expression (Shemer, Eisenberg et al. 1991).   
In the approximately 20 years since the Razin/Breslow papers were 
published there have been major improvements in epigenetic technology 
and understanding of molecular mechanisms and key players involved in 
histone modifications and epigenetic regulation (Jenuwein and Allis 2001).   
For this reason, as part of my thesis work, I revisited the original DNA 
methylation experiments with greatly improved modern technology.  I also 
examined the role of histone methylation and the histone code (not known 
at the time of the original experiments) in regulating ApoA-I gene 
transcription.  Especially with regard to the latter, I hoped to discover new 
aspects of the regulation of ApoA-I transcription that could be exploited to 








Figure 1.5 - Representation of the Two Major Epigenetics Modifications 
Epigenetics represents of the modifications of DNA not coded by the genetic code.  
The two major examples shown above are DNA methylation and histone 
modification.  Both exert their influence at differing times.  Methylation occurs on 
the actual DNA strand, while the histone modifications occur after DNA has wrapped 
itself into the nucleosome structure and then has its associated protruding histone 
tails.  All these histones, eventually wrap into more complex 3-dimensional structures 
to become chromosomes (Qiu 2006). 
 
Histone Code Determination 
 The histones that make up a nucleosome are subject to many forms 
of modification including, methylation, acetylation, phosphorylation, 
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ubiquitination and sumoylation (Bernstein, Meissner et al. 2007).  
However, these modifications appear to have a level of order to them; 
occurring at specific sites that make up what has become known as the 
histone code (Tomasetto, Regnier et al. 1995; Jenuwein and Allis 2001).  
Although the roles of many of these modifications are not fully understood, 
there is some insight into how histone N-terminal tail lysine acetylation and 
methylation regulate gene expression.  In general, histone N-terminal tail 
lysine acetylation appears to be associated with transcriptional activation.  
This may be due to neutralization of the positively charged histone lysines 
causing loosening of their attachment to the negatively charged DNA, 
thereby allowing for transcription factor insertion and gene activation 
(Bernstein, Meissner et al. 2007).   It appears that histone lysine 
methylation is more complicated as its effects on transcription appear to be 
residue and modification dependent.  In model organisms, it was shown for 
several genes, that tri-methylation of histone H3 lysine 4 (H3K4) activates, 
whereas tri-methylation of histone H3 lysine 27 (H3K27) represses 
transcription (Hake and Allis 2006).  These modifications and control 
mechanisms have never been described for the ApoA-I gene and therefore 





Histone Code Modification 
 The acetylation and deacetylation of the histone tails is catalyzed by 
histone acetyltransferases (HAT) and histone deacetylases (HDACs), 
respectively.  Over time, it was revealed that many of the histone 
acetyltransferases were previously identified as transcriptional co-activators 
that are recruited to genes by sequence specific transcriptional activators 
(Moggs and Orphanides 2004).  This suggested a novel role for 
transcriptional activators; namely the recruitment of factors to alter 
chromatin structure.   The key role of these chromatin alterations is 
illustrated in the way that xenobiotics target nuclear receptors and alter 
gene expression. For example, peroxisome proliferators, dioxins and 
estrogenic chemicals act via the peroxisome proliferator-activated receptor-
α, aryl hydrocarbon receptor and estrogen receptor, respectively (Moggs 
and Orphanides 2004).  These factors seem to induce alterations in 
chromatin structure that allow RNA polymerase II and its associated 
helpers to access the gene that needs to be transcribed.  The molecular 
mechanism for this process has been well studied for the estrogen receptor-
α (ERα) (Moggs and Orphanides 2001).   Ligand binding to ERα induces 
conformational changes that allow for 40-50 co-regulatory proteins to bind 
specific estrogen response element sequences near or within the ERα target 
genes.   
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Some of the co-regulators include nucleosome remodeling enzymes 
like BRG1 and BRM1 and histone-modifying enzymes like HAT, HDAC1 
and HDAC7 that ultimately allow de-compaction of local chromatin 
structure.  HDAC inhibitors such as Trichostatin A (TSA) or SiRNAs 
targeted to some of these HATs or HDACs could be used to perturb the 
histone code.  More specifically, this might help us understand that key 
switches that regulate the on versus off activity of the ApoA-I promoter.  
These specific histone markers might then be pharmacologically targeted to 
increase apoA-I expression and raise HDL cholesterol levels. 
Cholesterol’s Role in Regulation of Gene Expression 
 Cholesterol has the ability to regulate its own homeostatic balance at 
the transcriptional level by effect one of three pathways: the sterol 
regulatory element binding protein (SREBP) pathway, the liver X receptor 
pathway (LXR) or the unfolded protein response (UPR)/ endoplasmic 
reticulum (ER) stress pathway.  Each pathway will be discussed thoroughly 
in the next sections. 
The SREBP Pathway 
 The mechanisms that regulate the de novo synthesis, uptake and 
oxidative catabolism of lipids, involves a family of ER membrane 
associated transcription factors termed sterol regulatory element binding 
proteins or SREBPs (Raghow, Yellaturu et al. 2008).  As the regulation 
itself is intrinsically complicated, these transcription factors are subject to 
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various levels of feedback/feed-forward regulation at the transcriptional, 
translational and post-translational level. 
 The SREBP family of basic helix-loop-helix-leucine zipper (bHLH-
LZ) transcription factors is comprised of SREBP-1a, SREBP-1c and 
SREBP-2 encoded by two genes SREBP-1 and  SREBP-2 (Raghow, 
Yellaturu et al. 2008).  SREBP-1a and SREBP-1c differ only in the length 
of their N-terminal binding domain, which occurs due to the use of 
alternate promoters for the transcription of each (Eberle, Hegarty et al. 
2004).  More importantly, the genes, SREBP-1a, SREBP-1c and SREBP-2 
differ in their tissue specificity and target gene selectivity, which conveys 
each protein with a unique role (Espenshade 2006).    SREBP-1a and 
SREBP-1c regulate genes involved in the synthesis of monounsaturated and 
polyunsaturated fatty acids and their ultimate incorporation into 
triglycerides and phospholipids.  In contrast, SREBP-2’s role is primarily 
focused on activating genes involved in the uptake and biosynthesis of 
cholesterol (Espenshade 2006).  SREBP-1c is predominantly localized to 
the liver, while the other two are expressed fairly ubiquitously.  SREBP’s 
are known to regulate over 30 genes involved in various aspects of uptake 
and synthesis of cholesterol, fatty acids, triglycerides and phospholipids 
(Horton, Goldstein et al. 2002).   
The SREBP family members are localized to the ER as inert 
membrane proteins after synthesis (Goldstein, DeBose-Boyd et al. 2006).    
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In this state, they are an approximate 1150 amino acid precursor protein, 
depending on which SREBP, containing two hydrophobic membrane 
spanning regions separated by a short hydrophilic loop that projects into the 
lumen of the ER.  The N-terminal binding domain and the C-terminal 
regulatory domain both project into the cytoplasm (figure 1.6).  When 
sterols are replete, a protein called SREBP cleavage-activating protein 
(Kanno, Wu et al.) binds cholesterol and assumes a conformation that 
allows SREBP to bind the ER protein insulin induced gene (Insig) (Peng, 
Schwarz et al. 1997).  This binding, prevents SREBP-SCAP interaction 
with Coat protein complex-II (COPII) membrane vesicle formation and 
ultimately stops the translocation of this transcription factor to the Golgi 
(Raghow, Yellaturu et al. 2008).  In this sense, SCAP, which contains a 
sterol sensing domain similar to HMGCR, acts as a sensor for membrane 
cholesterol levels (Goldstein, DeBose-Boyd et al. 2006).   In the opposite 
situation, when the cell is in a cholesterol depleted state, SCAP dissociates 
from Insig, allowing for the translocation of the SCAP-SREBP complex 
from the ER to the Golgi (Raghow, Yellaturu et al. 2008).  As a built in 
feedback loop, oxysterols, cholesterol derivatives, interact with Insig in 
such a way that it will bind SCAP and prevent the translocation of the 
SCAP-SREBP proteins (Raghow, Yellaturu et al. 2008).   
Upon arrival to the Golgi, SREBPs undergoes two sequential 
proteolytic events, one mediated by the site 1 protease (S1P) extracellularly 
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and the other within the transmembrane domain by site 2 protease (S2P) 
(Espenshade 2006).  This releases the N-terminal transcription factor 
domain from the membrane allowing for translocation of SREBPs, as a 
dimer, to the nucleus by importin β (Rawson 2003).  Upon arrival to the 
nucleus, SREBPs binds to the sterol regulatory elements (SRE’s) in the 
promoter of target genes and activates transcription.  As a result, both 
cholesterol synthetic and cholesterol uptake genes are transcribed and the 
cell then replenishes its cholesterol stores and this then feeds back and 
inactivates SREBPs (Espenshade 2006).  Further regulating this well 
balanced homeostatic cycle, is the half life of nuclear SREBP, as it is 





Figure 1.6 - SREBP Role in Cholesterol Regulation 
Above is representation of the fate of the SREBP pathway.  When sterols are high, 
SCAP through its SSD domain binds Insig (not pictured) and sequesters SREBP in 
the membrane of the ER.  Upon sterol depletion, the SCAP-SREBP complex is 
allowed to move to the Golgi, where it is cut into its active precursor by two 
proteases, S1P and S2P.  The shortened active form of SREBP is then moved to the 
nucleus where it activates transcription of genes involved in cholesterol synthesis  
and uptake.  
 
The LXR Pathway 
 The second important family of transcription factors involved in 
cholesterol regulation of gene expression is liver X receptor or LXR.  LXRs 
regulate genes involved in reverse cholesterol transport, dietary cholesterol 
absorption, bile acid metabolism, glucose metabolism and fatty acid 
biosynthesis (Repa and Mangelsdorf 2002).    
 The LXR receptor genes, LXR-α and LXR-β, are members of the 
nuclear hormone receptor superfamily of ligand-activated transcription 
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factors (Repa and Mangelsdorf 2002).  Also known as NR1H3 and NR1H2 
respectively, the proteins are composed of a central DNA-binding domain, 
consisting of a zinc-finger and a large lipophilic ligand binding core that 
binds its endogenous ligands, oxysterols and other intermediates of the 
cholesterol biosynthesis pathway (Tontonoz and Mangelsdorf 2003).  As is 
alluded to in its name, LXR-α and LXR-β are most highly expressed in 
liver.  However, while LXR-β is ubiquitously expressed, LXR-α’s 
expression beyond the liver is restricted to the spleen, adipose tissue, lung 
and pituitary glands.  
 Interestingly, and one of the major reasons LXR’s have become 
studied in the atherosclerotic research community, is LXR’s role in 
inhibiting atherosclerosis.  As stated before, mice are particularly resistant 
to forming atherosclerotic lesions.  This is due to multiple variables, but 
one of them is the mouse specific up-regulation of a gene called cholesterol 
7α hydroxylase (CYP7A1), the rate limiting enzyme in bile acid synthesis 
and a key component of RCT (Repa and Mangelsdorf 2002).  CYP7A1, 
also happens to be the first gene described as an LXR target gene (Peet, 
Turley et al. 1998).  Consistent with this anti-atherosclerotic role, LDLR-/- 
or ApoE-/- mice fed agonists for LXR show significant reduction in the size 
of their atherosclerotic lesions (Claudel, Leibowitz et al. 2001; Joseph, 
McKilligin et al. 2002).  Further investigation into the effect of LXR on 
atherosclerotic development led researchers to discover LXR’s role is most 
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widely exerted in macrophages.  This was well exemplified when 
researchers conducted a bone marrow transplant experiment.  First 
endogenous monocytes and macrophages from LDLR-/- and ApoE-/- mice 
were irradiated and destroyed (Tangirala, Bischoff et al. 2002).  
Subsequently, the mice received bone marrow transplants from either WT, 
LXR-α-/- or LXR-β-/- mice to replace the lost macrophages and monocytes.  
The bone marrow and thus the macrophages from LXR-α-/- or LXR-β-/- 
transplants were less functional compared to wild-type, amassing larger 
plaque lipid droplets.  Furthermore the mice who received their bone 
marrow from LXR-α-/- or LXR-β-/-  mice had significantly greater 
atherosclerotic lesions when compared to the mice transplanted with WT 
bone marrow (Tangirala, Bischoff et al. 2002).   
On a molecular level, upon ligand binding, LXRs undergo a 
conformational change that allows it to bind retinoid X receptor (RXR) 
which acts as a heterodimer to activate transcription of selected genes 
(Repa and Mangelsdorf 2002).    In contrast to SREBP, LXR is expressed 
when endogenous cholesterol levels are high.  Ligands for LXR have been 
identified as oxysterols, as well as glucose and D-glucose-6-phosphate 
(Repa and Mangelsdorf 2002; Mitro, Mak et al. 2007).  Among oxysterols, 
22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol and 24(S), 25 
epoxycholesterol have been identified as high affinity ligands for LXR 
(Lala, Syka et al. 1997; Schoonjans, Brendel et al. 2000; Fu, Menke et al. 
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2001).   Interestingly, 27-hydroxycholesterol, the most abundant oxysterol 
in plasma is only a weak activator of LXR.  Additionally, synthetic, non-
steroidal LXR-selective agonists exist like T0314407, T0901317, GW3965 
(Collins, Fivush et al. 2002). 
  
 
Figure 1.7 - Roles of LXR in the Liver, Peripheral Tissue and Intestine.          
Nuclear hormone receptors (LXR and RXR) coordinate reverse cholesterol transport 
from peripheral tissues to the liver allowing for cholesterol conversion into bile acids 
and cholesterol excretion in the intestine. As described, they help by activating 
expression of the cholesterol transporter ABC1 in cholesterol loaded peripheral cells, 
notably macrophage foam cells, leading to enhanced efflux of free cholesterol and the 
eventual formation of mature HDL. Additionally, LXR’s up-regulate CETP, 
CYP7A1, LPL, PLTP SR-B1 and other genes involved in RCT and eventual 





LXRs also act as regulators of hepatic lipogenesis and glucose 
metabolism.  LXRs enhance SREBP-1c expression which can lead to 
hypertriglyceridemia (Schultz, Tu et al. 2000).  Additionally, treatment of 
mice with synthetic LXR ligands can cause hepatic steatosis (Schultz, Tu et 
al. 2000).  LXR’s can activate glucokinase, phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase, thus decreasing hepatic glucose 
output and increasing hepatic glucose utilization (Jamroz-Wisniewska, 
Wojcicka et al. 2007).   It has even been shown that LXRs have anti-
inflammatory activity, repressing genes like iNOS, Cox2, IL-6, IL-1, 
βMCP-1, MCP-3 and MMP9 after LPS, TNF-α or IL-1-β stimulation (Yan 
and Olkkonen 2008). 
Unfolded Protein Response / Endoplasmic Reticulum Stress Response 
The ER is the repository of nearly 50% of cellular membranes, a 
major site of calcium storage, the major location of sterol and lipid 
synthesis and the site of protein synthesis.  The ER plays a critical role in 
sensing cellular homeostasis (Schroder 2008).    Crucial to the cell, is that 
only properly folded and modified proteins are exported from the ER to the 
Golgi, while all other mishaps in protein production are degraded.  Three 
major pathways have been elucidated that can disrupt this process and 
induce the unfolded protein response (UPR) or ER stress response.  They 
are the generation of reactive oxygen species (Gross, Wan et al.), excessive 
secretory protein synthesis and cholesterol overloading of the ER (Shen, 
 33
Zhang et al. 2004).  The UPR is characterized by the activation of three 
transmembrane proteins, PKR-like ER protein kinase (Bartz, Kern et al.), 
inositol requiring enzyme 1 (IRE-1) and activating transcription factor 6 
(ATF6) (Foufelle and Ferre 2007). 
 Mechanistically, these factors are regulated in a similar manner to 
the SREBP proteins.  Normally bound to Bip/GRP78, an ER chaperone 
protein, the three proteins are sequestered to the ER membrane (Kaufman, 
Scheuner et al. 2002).  However, BiP binds to misfolded proteins, which 
then allows for the release of PERK, IRE-1 and ATF6.  Perk, 
phosphorylates elf2α, attenuating translation of most mRNAs (Fels and 
Koumenis 2006).  IRE-1 homodimerizes and undergoes 
autophosphorylation which eventually leads to splicing of XBP1 (Foufelle 
and Ferre 2007).  ATF6 translocates to the Golgi and eventually shuttles to 
the nucleus to activate expression of genes involved in the UPR response 
(Haze, Yoshida et al. 1999).  
 The initial phase of the UPR focuses on recovery.  The three proteins 
orchestrate a symphony of changes that include, increasing the ER folding 
capacity by increasing the ER synthesis of phospholipids and re-esterifying 
sterols.  Additionally, they down-regulate the overall load on the ER, by 
decreasing overall transcription and translation (Foufelle and Ferre 2007).  
However, if all the countermeasures fail, apoptotic pathways are eventually 
activated to eliminate the perceived unhealthy cell.  It is this eventual fate 
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that has implicated UPR in disease such as atherosclerosis, diabetes and 
neurodegenerative diseases (Marciniak and Ron 2006; Scheper and 
Hoozemans 2009). 
 Accumulation of free cholesterol in the ER is a known activator of 
the UPR (Tabas 2002).  Normally the cell does not experience this 
difficulty, due to the activity of ACAT, but in atherosclerosis these 
mechanisms are overwhelmed and the UPR is activated.  Specifically, 
macrophages in plaques start accumulating excess free cholesterol via 
scavenger receptors whose expression is independent of cellular cholesterol 
status (Zhou, Lhotak et al. 2005).  Initially, the UPR enhances cell survival, 
but eventually the intracellular free cholesterol is too great and the cell 
undergoes apoptosis exacerbating the progression of atherosclerosis (Zhou, 
Lhotak et al. 2005).  
Intracellular Cholesterol Transport 
 Cholesterol is essential for mammalian cell membranes, but the 
cholesterol:protein ratio varies considerably between membranes (Ikonen 
2008).   Cholesterol is enriched in the plasma membrane (PM), where it 
constitutes 20% to 45% of lipid molecules (Maxfield and Wustner 2002).    
It is also abundant in the endocytic recycling compartment and in the Golgi, 
especially the trans-Golgi compartments (Mukherjee, Zha et al. 1998).  In 
contrast, the other major membrane constituent of the cell, the ER, which 
has already been described as a major player in cholesterol regulation, has a 
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low cholesterol content, estimated at approximately 1% of total cellular 
cholesterol (Lange 1991).  Interestingly, the membranes of the ER and PM 
are close to equal in area, but yet still have striking differences in 
cholesterol concentration (Liscum and Munn 1999).   It is these contrasting 
characteristics of the ER, be its involvement in sterol homeostasis, ranging 
from controlling signaling pathways such as SREBP and the UPR discussed 
previously to regulating its own surprisingly low cholesterol levels, that 
spur the interest of the researcher community in intracellular cholesterol 
sorting. 
The exact mechanisms responsible for creating and maintaining this 
drastic difference in membrane cholesterol levels has not been determined.   
However, transport and sorting mechanism must exist to include or exclude 
cholesterol from organelles.   Understanding this is crucial to understanding 
overall sterol homeostasis and ultimately relates back to questions 
concerning the development of atherosclerosis (Soccio and Breslow 2004).    
It has been known for some time that cholesterol is transferred 
between intracellular compartments by both vesicular and non-vesicular 
mechanisms (Soccio and Breslow 2004).  Vesicular trafficking, is a 
mechanism for moving membrane components and luminal cargo between 
subcellular organelles along cytoskeletal tracks in an ATP dependent 
manner (Mobius, van Donselaar et al. 2003; Ikonen 2008).  Disruption of 
the cytoskeleton with Brefeldin A or depleting ATP with metabolic poisons 
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have both been shown to disrupt intracellular sterol transport by vesicular 
mechanisms (Prinz 2007).   
In contrast, there is also evidence that cholesterol is transported by 
non-vesicular mechanisms.   This includes transportation of cholesterol by 
cytosolic lipid transfer proteins or directly, by membrane contact.  Blocking 
vesicular pathways up to as high as 90%, does not significantly alter the 
cholesterol gradient across the organelles, suggesting that a non-vesicular 
mechanism may play an important role in compensating the cellular 
cholesterol trafficking (Prinz 2007).  Further highlighting the proposed role 
for non-vesicular cholesterol trafficking, there are no known vesicular 
methods for transferring cholesterol between various cellular compartments 
and the mitochondria; the location of steroid synthesis.  This also holds true 
for movement of sterols between intracellular organelles and lipid droplets, 
lipid storage depots consisting of a core of sterol esters and triglycerides 
(Prinz 2007). Therefore, it seems that there is much to be learned about the 
non-vesicular pathways of transport and its role in cholesterol movement 
intracellularly. 
 Non-vesicular transporters or cytosolic lipid transfer proteins are 
proteins that contain a hydrophobic pocket, providing shelter for a 
hydrophobic cholesterol molecule as it travels through the hydrophilic 
cytosol.  These proteins fall into five families.  The following sections will 
cover these families in depth, starting with the niemann pick C proteins and 
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then proceeding to the caveolins, the oxysterol binding protein-related 
proteins, the sterol carrier protein 2 and ending with an extra emphasis 
given to the steroidogenic acute regulatory-related lipid transfer domain 
proteins, of which one member, StARD4, is the basis of much of the work 





















Figure 1.8 – Vesicular and Non-Vesicular Intracellular Cholesterol Transport.          
Cholesterol has two mechanisms by which it can travel through the hydrophilic 
cytosol, vesicular and non vesicular.  Vesicular encompasses the classical pathways 
involved in receptor mediated endocytosis exemplified by the absorption of an LDL 
particle.  Non vesicular is protein mediated by families of proteins such as the StAR 
proteins. 
 
Niemann Pick C Proteins 
Niemann Pick Type C (NPC) is a fatal neurodegenerative disease, 
that is an autosomal recessive lipid storage disorder characterized by 
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intracellular free cholesterol accumulation in late endosomal/lysosomal 
cellular compartments (Soccio and Breslow 2004).  Mutations in either of 
the genes, NPC1 or NPC2 is the genetic cause for the disease (Sturley, 
Patterson et al. 2004).  NPC1 is a late endosomal membrane protein with 13 
predicted transmembrane segments, including a sterol sensing domain 
(Prinz 2002).   NPC2 is a soluble cholesterol-binding protein in the lumen 
of late endosomes and lysosomes (Naureckiene, Sleat et al. 2000).  
Evidence points to a role for the two proteins in the pathway necessary for 
trafficking LDL derived cholesterol out of lysosomes (Sleat, Wiseman et al. 
2004).  Strangely, although NPC2 has been shown to bind cholesterol with 
a stoichiometery of 1:1, the structure of NPC2 has been solved and appears 
to be too small to accommodate a cholesterol molecule(Friedland, Liou et 
al. 2003; Ko, Binkley et al. 2003).  A recent paper by Brown and Goldstein, 
reveals, by elucidation of the structure NPC, the process by which the 
NPC1 and NPC2 transfer cholsterol.  The working model is that after 
lysosomal hydrolysis of LDL cholesterol esters, cholesterol binds NPC2, 
which transfers it to NPC1 N-Terminal domain, reversing its orientation 
and allowing insertion of its isooctyl side chain into the outer lysosomal 
membrane (Kwon, Abi-Mosleh et al. 2009). 
Although most models of NPC involve defective or slowed transport 
of cholesterol away from late endosomes, the precise mechanisms 
controlling the process are unknown.  The two main components of lipid 
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rafts, cholesterol and sphingomyelin, have high affinity for one another and 
accumulation of one can cause accumulation of the other (Simons and 
Gruenberg 2000).  In concordance, NPC1 deficient neurons store a greater 
amount of sphingomyelin than cholesterol (Gondre-Lewis, McGlynn et al. 
2003).  However, work in NPC1 deficient mice show neuronal 
accumulation of cholesterol (Reid, Sakashita et al. 2004).  Alternatively, it 
is possible that NPC1/2’s protein mutations cause general late endosome 
problems.  This is supported by over-expression studies done with Rab7 
and Rab9, two GTPases involved in late endosomal function, that can 
correct the cholesterol and sphingomyelin accumulation associated with 
NPC cells (Choudhury, Dominguez et al. 2002).   On an atherosclerotic 
background, ApoE-/- mice whose macrophages are homozygous for NPC1 
deficiency have larger lesions with evidence of arterial medial degradation 
and atherothrombosis (Welch, Sun et al. 2007).   
The Caveolins 
 Caveolins are abundant membrane proteins associated with 
cholesterol and sphingomyelin (Prinz 2007).  When caveolins oligomerize, 
they form caveolae; cholesterol and sphingomyelin rich flask shaped 
membrane invaginations found in some cells.  Caveolins are likely to play 
important roles in cholesterol homeostasis and distribution (Parton and 
Simons 2007).  It has been suggested that caveolins transport cholesterol 
from the ER to the PM as a part of complex, much like a plasma 
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lipoprotein, with heat shock protein 56, cyclophilin A and cyclophilin 40 
(Prinz 2007).  However, the exact role of caveolins in cholesterol transport 
remains debated. 
 There are three caveolins; 1, 2 and 3.  Caveolins are located on the 
cytoplasmic side of caveolae and serve as structural components of 
caveolae and as scaffolding proteins for various signaling molecules 
(Cohen, Hnasko et al. 2004).  Surprisingly, given caveolin-1’s role in 
caveolae formation, caveolin-1 mouse knockouts are viable with normal 
lipid profiles (Drab, Verkade et al. 2001).  Bred onto the atherosclerotic 
background, caveolin-1-/- ApoE-/- double knockout mice have reduced 
atherosclerosis despite higher levels of plasma non-HDL cholesterol and 
triglycerides (Frank, Lee et al. 2004).  It might be that caveolins play a role 
in uptake of cholesterol in macrophages, explaining the reduction found in 
the atherosclerosis mouse model, however much more is needed to be done 
to elucidate the role of the caveolins in the intracellular non vesicular 
pathways.  
 Oxysterol Binding Protein (OSBP) – Related Proteins (ORPs) 
OSBP was initially identified because it binds oxysterols, 
oxygenated cholesterol derivatives and regulators of cholesterol 
metabolism (Kandutsch and Shown 1981).  ORP’s are part of a large family 
of lipid binding proteins related to OSBP, of which there at least 12 
members, that play numerous roles including lipid distribution and 
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metabolism, cell signaling and vesicular transport (Prinz 2007).  
Structurally, ORP’s contain the C-terminus lipid binding domain with the 
signature OSBP motif, EQVSHHPP.  The N-terminus is variable and 
contains a range of motifs like FFAT, pleckstrin homology or an anykrin 
repeats.  Alternative splicing of the ORPs is common and results in long 
and short forms of the proteins with different subcellular localizations and 
binding specificities.     A large amount of the work on ORPs has been done 
in yeast S. cerevisiae, which has seven OSH (OSBP homolog) proteins 
(Prinz 2007).  Yeast mutants for any one of the seven OSH genes have little 
to no defect in PM to ER sterol transfer suggesting a level of redundancy 
(Raychaudhuri, Im et al. 2006).  However, conditional deletion of all seven 
genes slows exogenous sterol transport, causes vacuolar fragmentation and 
accumulation of lipid droplets ultimately ending in cell death (Beh, Cool et 
al. 2001; Beh and Rine 2004)   
Unfortunately, little is known about the mammalian ORPs and 
whether they work as sterol transfer proteins is yet to be elucidated.  ORPS 
are made up of six subfamilies based on sequence homology.  They are 
OSBP and ORP4, ORP1/2, ORP/8, ORP3/6/7 and ORP 9/10/11.  OSBPs 
localize to the cytoplasm, but relocate to the Golgi upon treatment with 25-
hydroxycholesterol (Fairn and McMaster 2008).    Over-expression of 
OSBP increases cholesterol and sphingomyelin synthesis, while RNAi 
knockdown shows no change in cholesterol or fatty acid synthesis (Fairn 
 42
and McMaster 2008).  In mice, adenoviral over-expression of OSBP in 
liver leads to an increase in plasma VLDL and TG concentrations, due to an 
up-regulation of SREBP-1c (Yan and Olkkonen 2008). Other ORP’s like 
Orp-1 have been shown to increase atherosclerotic lesions in an LDLR-/- 
mice when over-expressed in macrophages, suggesting a role in 
macrophage sterol metabolism (Yan and Olkkonen 2008).  ORP2 over-
expression in CHO or Hela cells causes up-regulation of cellular cholesterol 
efflux , decreased cholesterol esterification and reduced triglycerides  
(Laitinen, Lehto et al. 2002).  Although the roles and characteristics of 
some of the other ORP’s has been described, little is known about the role 
of these proteins in-vivo and there is much room for researchers to discover 
novel aspects of OSBP behavior and ultimately intracellular cholesterol 
transport. 
Sterol Carrier Protein 2 (SCP-2) 
SCP-2 is a small 13.3 kDA protein that is also called non-specific 
lipid transfer protein (nsLTP).  The protein is formed by the cleavage of 
two other larger proteins, SCP-x and pro-SCP-2, both of which are encoded 
by the same gene with distinct promoters (Prinz 2007).  Both proteins are 
made with a c-terminal peroxisomal targeting signal and are therefore likely 
involved in β-oxidation of fatty acids.  As further evidence of this, mice 
lacking the gene for SCP-2 have defects in fatty acid oxidation (Seedorf, 
Raabe et al. 1998).   
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Additional implicated roles for SCP-2 include transport of sterols 
and other lipids between sub-cellular compartments.  A fraction of SCP-2 is 
found in the cytoplasm and numerous studies have demonstrated that SCP-
2 can transfer cholesterol between liposomes and/or membranes (Gallegos, 
Atshaves et al. 2001).  Much additional work is needed in order to further 
elucidate the role of SCP-2 to elucidate its role in intracellular transport. 
Steroidogenic Acute Regulatory-Related Lipid Transfer Domain 
Protein Family (StAR Protein Family) 
 StAR-related lipid transfer (START) domains are ~210 amino acid 
lipid binding domains implicated in intracellular transport, cell signaling 
and lipid metabolism.  The first described member of the family was 
steroidogenic acute regulatory protein (StAR), which is responsible for 
transfer of cholesterol to the mitochondria in steroid producing cells 
(Stocco 2001).  The human and mouse genomes each have 15 genes 
encoding start domains and further phylogenetic analysis divides the 
families into six subfamilies (Soccio, Adams et al. 2002).  The X-ray 
crystal structures of MLN64, StARD4 and phosphatidylcholine transfer 
protein (PCTP) have all been solved.  All three share a helix-grip fold with 
α-helices at the N and C terminus separated by nine β-sheets and two α-
helices (Soccio, Adams et al. 2002).  The following sections of the 




StARD name            Other names                                   Mouse                    Human  
 
StARD1                    StAR                                         8, 24.5 Mb              8, 37.4 Mb  
StARD2                    PCTP                                       11, 90.7 Mb           17, 53.6 Mb  
StARD3                    MLN64, es64, CAB1                11, 99.1 Mb          17, 37.3 Mb  
StARD4                   CRSP                                       18, 33.4 Mb            5,110.5 Mb  
StARD5                   None                                          7, 73.3 Mb           15, 77.6 Mb  
StaRD6                   None                                          18, 70.8 Mb          18, 52.0 Mb  
StARD7                   GTT1                                        2, 128.3 Mb            2, 94.7 Mb  
StARD8                   KIAA0189-RhoGAP                   X, 81.9 Mb           X, 64.1 Mb  
StARD9                   KIAA1300                                 2, 121.1 Mb          15, 38.4 Mb  
StARD10                 PCTP-like, SDCCAG28, CGI-5 7, 91.1 Mb          11, 74.8 Mb  
StARD11                 GPBP, COL4A3BP                   13, 93.9 Mb            5, 73.5 Mb  
StARD12                 DLC-1, Arhgap7, p122-RhoGAP 8, 35.5 Mb           8, 12.7 Mb  
StARD13                GT650, 4902678-RhoGAP        5, 150.3 Mb          13, 31.7 Mb  
(StARD14)              CACH                                         13, 88.9 Mb           5, 80.8 Mb  
(StARD15)              THEA, BFIT, KIAA0707            4, 104.5 Mb           1, 54.8 Mb 
 
 
Table 1.1 - Nomenclature and Chromosomal Locations of the START Genes 
All human START genes except CACH and THEA have been assigned formal names 
of StARD1—StARD13, but some common names are widely used. Physical map 
positions (chromosome, position in megabases) in the mouse and human genomes are 
based on the Ensembl data base (www.ensembl.org)  
   
 
Figure 1.9 - Phylogenetic Structure of the START Family. 
The 15 human START domain proteins were aligned using ClustalW and the 
resulting phylogenetic tree with 6 subfamilies was created.  Start domains are 
represented in green and other common regions in grey.  (4tm - four transmembranes, 
Pre - mitochondrial precursor, Thio – acyl-CoA thioesterase). 
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The StAR Subfamily (StAR & MLN64) 
StAR 
 The rate limiting step in steroidogenesis is controlled by StAR’s 
delivery of cholesterol to the P450 side chain cleavage enzyme residing on 
the inner mitochondrial membrane (IMM), which converts cholesterol to 
pregnenolone (Miller and Strauss 1999).   Phosphorylation of pre-existing 
StAR and synthesis of new StAR is the result of pituitary hormone 
signaling (Miller and Strauss 1999).  Mouse knockouts of StAR have a 
phenotype mimicking congenital lipoid adrenal hyperplasia, which have 
marked defects in steroidogenesis in the adrenal glands and gonads (Caron, 
Soo et al. 1998).  However, there is some evidence to point to an alternative 
mechanisms of steroidogenesis, as StAR null fetuses produce normal 
amounts of placental progesterone (Bose, Sugawara et al. 1996).   
 The importance of StAR is due to its role in transporting cholesterol 
to the IMM, a destination that proves difficult to reach as cholesterol must 
first arrive at the outer mitochondrial membrane (OMM) and then transfer 
through the inter-membranous space to get to the IMM.  Originally 
synthesized as a 37 kDa precursor, StAR is cleaved at its N-terminus to is 
active 30kDa form upon arrival in the mitochondria (Bose, Baldwin et al. 
2000; Soccio and Breslow 2003).  It is likely, that StAR’s activity occurs in 
the OMM as studies where StAR is fused to mitochondrial proteins in the 
OMM, IMM and inter-membranous space only have activity at the OMM 
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(Bose, Lingappa et al. 2002).  Unclear is how StAR performs other 
functions.   It has been proposed that perhaps StAR simply drops off 
cholesterol.  Or perhaps, StAR in its molten globule state alters the OMM 
to facilitate cholesterol desorption to the IMM (Bose, Baldwin et al. 2000).  
Whatever the role might be, it is clear that StAR plays a vital role in 
steroidogenosis in the mitochondria. 
MLN64 (StARD3) 
 First discovered as a gene amplified in breast, gastric and esophageal 
cancer, MLN64 localizes to late endosomes (Akiyama, Sasaki et al. 1997).  
Its association with cancers is probably due to its close genetic proximity to 
the oncogene c-erb-B2 with which it coamplifies (Tomasetto, Regnier et al. 
1995).  Structurally, MLN64’s N-terminus includes four transmembrane 
helices and the C-terminus shares 37% homology with StAR (Moog-Lutz, 
Tomasetto et al. 1997).  Its X-ray crystal structure is consistent with a  
molecule capable of binding cholesterol in a 1:1 manner (Tsujishita 2003).   
Much like StAR, MLN64 transfers cholesterol in-vitro and stimulates 
steroidogenosis (Watari, Arakane et al. 1997).   MLN64 is detectable in all 
tissues and could be responsible for the placental steroidogenesis 
mentioned earlier.   
 MLN64 has an additional role as a participant in the NPC pathway.  
It is thought, that after LDL deposits cholesterol into the endosome, NPC2, 
NPC1 and then MLN64 might act sequentially to move cholesterol to its 
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eventual cytosolic acceptor (Strauss, Liu et al. 2002).  Unfortunately, 
MLN64 has not been reported in NPC disease and mouse knockouts of 
MLN64 were overall phenotypically normal (Kishida, Kostetskii et al. 
2004).   
StARD4 Subfamily: StARD4, StARD5 & StARD6 
 StARD4, StARD5 and StARD6 form a family of START domain 
proteins based on phylogenetic analysis and are closely related to StAR and 
MLN64.  StARD4 was identified first as a gene down-regulated 2-fold by 
dietary cholesterol in a microarray study (Soccio, Adams et al. 2002).  
Based on this proximity to other START domain proteins and the 
microarray data, it is likely that the StARD4 subfamily members participate 
in cholesterol metabolism (Soccio, Adams et al. 2005).   
StARD4 and StARD5 are both widely expressed with their highest 
levels reached in the liver, whereas StARD6’s expression is isolated to the 
testis and neurons (Soccio, Adams et al. 2005).  StARD4 and StARD5 
share 30% amino acid homology (Soccio and Breslow 2003).  Both 
proteins bind cholesterol as a ligand, but StARD5 additionally binds 25-
hydroxycholesterol (Rodriguez-Agudo, Ren et al. 2006).  StARD4 and 
StARD5 were both shown to be able to activate steroidogenosis by the 
mitochondrial p450scc when analyzed by co-transfection assays for StAR-
like activity (Ponting and Aravind 1999; Soccio, Adams et al. 2005).  It has 
also been postulated that StARD4 and StARD5 might deliver cholesterol in 
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rate limiting manner to mitochondrial cyp27, which generates 27-
hydroxycholesterol, the initial step in what is known as the alternative bile 
acid synthesis pathway (Pandak, Ren et al. 2002).  Additionally, 27-
hydroxycholesterol is an activator of LXR and RCT, implicating a role for 
StARD4 in cholesterol removal from the body.   The bile acid theory has 
been supported by data showing that transfection of an overexpressing 
StARD4 plasmid in primary hepatocytes is capable of increasing the rate of 
bile acid production (Rodriguez-Agudo, Ren et al. 2008).  This same study 
also showed an increase in neutral lipid droplets, identified by oil red o 
staining.    
Interestingly, in both mouse liver and cultured cells, StARD4, unlike 
StARD5, shows the characteristics of a gene regulated by the SREBP 
pathway.  In concordance, the StARD4 promoter has a functional SRE 
element (Ponting and Aravind 1999).  In contrast, StARD5 is not regulated 
by sterols, but rather ER stress.  The ER in general is a cholesterol poor 
organelle, despite its role in cholesterol synthesis and therefore, StARD5 
might play a role in helping to reduce ER stress (Soccio and Breslow 2003).   
However, as an added wrinkle, StARD4 has an ERSE like element in its 
promoter and can be up-regulated by ER stress through the ATF6 
transcription factor (Yamada, Yamaguchi et al. 2006).  StARD6 on the 
other hand, expressed exclusively in the testis might be important for male 
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fertility as sterols play key roles from meiosis to capacitation (Byskov, 
Baltsen et al. 1998; Travis and Kopf 2002).   
To better understand the role of StARD4 physiologically, a major 
part of the work done in this thesis is focused on characterizing and 
understanding the phenotype of the StARD4 mouse knockout. 
PCTP Subfamily: PCTP (StARD2), StARD7 (GTT1), StARD10 & 
StARD11 (GPBP/CERT) 
 A little more distantly related then some of the other START domain 
proteins, the PCTP subfamily’s only common homology to StAR proteins 
is its START domain.  Its exonic organization differs and PCTP proteins 
also bind a variety of different lipids (Soccio and Breslow 2003).   
PCTP (StARD2) 
 PCTP or phosphatidylcholine transfer protein is an extremely 
specific lipid transporter binding to PC in a 1:1 stochiometric manner.  It is 
responsible for intermembrane transport of PC and no other lipids or 
phospholipids (Wirtz 1991; Kanno, Wu et al. 2007).   It is thought that 
PCTP transfers PC from its site of synthesis at the ER to the plasma 
membrane and mitochondria.  In support of this, upon treatment of cells 
with clofibrate,  PCTP transfers to the mitochondria; a movement induced 
by a phosphorylation at serine 110 (de Brouwer, Westerman et al. 2002).   
Widely expressed, PCTP’s highest levels are found in liver.  PCTP 
knockout mice exist and have been reported to have normal bile excretion 
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levels, normal production of lung surfactant, composed primarily of PC and 
normal leukotriene biosynthesis, but the study was confounded by low bile 
excretion levels in wild type mice that might have masked the results in the 
knockouts (van Helvoort, de Brouwer et al. 1999).   When the mouse 
knockout is challenged by a lithogenic diet, known to promote cholesterol 
gallstone formation, biliary secretion rates of bile acids, cholesterol and 
phospholipids are increased, yet the mice maintain normal hepatocellular 
secretion of PC (Wu, Hyogo et al. 2005).  Over-expression of PCTP in 
chinese hamster ovary cells (CHO) results in a dose dependent increase in 
the efflux of lipids through the ABCA1 transporter suggesting that PCTP 
might play a role in replenishing the plasma membrane with PC after it gets 
utilized by ABCA1 (Baez, Barbour et al. 2002). 
Finally, at 6 months of age, PCTP and ApoE double knockouts had a 
slight reduction in atherosclerosis, which in males was accompanied by a 
decrease in plasma cholesterol (Wang, Baez et al. 2006). 
StARD7 (GTT1) 
Few functional studies of StARD7 or GTT1 (gestation trophoblastic 
tumor 1) have appeared in the literature.  StARD7 was first identified by its 
over-expression in choriocarcinoma cell lines compared to cells lines 
derived from normal trophblastic tissue and nonmalignant hydatidiform 
moles (Durand, Angeletti et al. 2004).  It has also been shown to mediate 
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the intracellular trafficking of phosphatidylcholine to mitochondria 
(Horibata and Sugimoto). 
 StARD10 
StARD10 was identified as a protein over-expressed in breast 
cancer.  It is known to bind PC and phosphatidylethanolamine (PE) with a 
preference for lipids containing palmitoyl and stearoyl chains in the SN-1 
position and fatty acyl chains in the SN-2 position (Olayioye, Vehring et al. 
2005).   StARD10 mRNA is found in many tissues like the testis, kidneys 
and intestine (Soccio and Breslow 2003).  There is still much to be learned 
about the role of StARD10 in lipid metabolism. 
 StARD11 (GPBP, CERT) 
There are two StARD11 transcripts; the long form Goodpasture 
antigen-binding protein (GPBP) and the short form ceramide transfer 
protein (CERT) (Hanada, Kumagai et al. 2003).   Both forms are expressed 
highly in striated muscle and brain, but poorly in placenta, lung and liver.   
GPBP has a N-terminal pleckstrin homology, two serine rich 
domains and a C-terminal START domain (Soccio and Breslow 2003).  It 
binds and phosphorylates Goodpasture antigen, the target of autoantibodies 
in goodpasture syndrome (Raya, Revert-Ros et al. 2000).   Although 
lacking a conventional serine/threonine domain, it is inactive if missing the 
C-terminus.  The presence of a kinase site is unknown and it is speculated 
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that the START domain is regulatory and not catalytic (Soccio and Breslow 
2003).   
Both isoforms can bind and transport ceramide, in a stochiometric 
1:1 fashion, leading to the hypothesis that the proteins are responsible for 
delivery of ceramide from the ER, the site of synthesis, to the Golgi where 
it is converted to sphingomyelin (Hanada, Kumagai et al. 2003).   Knockout 
of the StARD11 homologue in Drosophila Melongaster results in premature 
death, reduced ATP, reduced thermal tolerance, increased glucose levels 
and a reduction in sphingomyelin that leads to increased membrane fluidity 
(Rao, Yuan et al. 2007).   Finally, it seems StARD11 might interact with 
other sterol transporters, as RNAi knockdown of OSBP decreases 
StARD11 activity and sphingomyelin synthesis (Perry and Ridgway 2005).   
 Acyl-CoA Thioesterase Subfamily: StARD14 & StARD15  
 StARD14 (BFIT, ACOT & THEA) 
StARD14, also known as brown fat-inducible thioesterase (BFIT), 
acyl-CoA thioester hydrolase 11 (ACOT11) or thioesterase adipose 
associated (THEA), appears in obesity models due to its role in energy 
metabolism (Adams, Chui et al. 2001).  It has 60% homology to StARD15 
(or better known as cytosolic acetyl-CoA hydrolase – CACH), but lacks the 
acetyl-CoA hydrolase activity (Suematsu, Okamoto et al. 2001).  Instead, it 
seems to hydrolyze medium and long chain acyl-CoA’s (Adams, Chui et al. 
2001).  Humans produce two splice variants that encode different c-
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terminal regions and whose expression pattern varies by tissue (Adams, 
Chui et al. 2001).  The change in C-terminus leads to different α-helix lids 
and therefore might lead to different lipid binding profiles (Soccio and 
Breslow 2003).  In correspondence with its nomenclature, StARD14 
mRNA in mouse brown adipose tissue is induced by cold exposure and 
decreases by 2.5 fold in obese (ob/ob) mice compared to lean wild-type 
littermates (Adams, Chui et al. 2001). Finally, StARD14 maps to mouse 
chromosome 4 in the dietary obese locus, suggesting a role for StARD14 in 
energy metabolism.   
 StARD15 (CACH, ACOT12) 
StARD15, also known as cytosolic acetyl-CoA hydrolase (CACH) 
or acyl-CoA thioesterase (ACOT12), has hydrolase activity for acetyl-CoA 
(C2) and low activity for short chain acyl-CoAs (C4 - C6), but lacks activity 
for medium (C12) and long chain acyl-CoA (C14) (Suematsu, Okamoto et al. 
2001).  It therefore might act to maintain an equilibrium between acetyl-
CoA and its coenzyme A-SH.  Interestingly, starvation and a fat free diet 
have both been shown to increase activity, suggesting that StARD15 also 
plays a role in regulation of fatty acid oxidation and synthesis (Matsunaga, 
Isohashi et al. 1985).  Additionally, activity is increased by cholesterol 
feeding and by inhibitors of cholesterol activity, both of which normally 
decrease the level of acetyl-CoA intracellularly (Ebisuno, Isohashi et al. 
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1988).  Finally, both sterotozotocin induced diabetes and clofibrates elevate 
StARD15 activity. 
StARD15 is active enzymatically when it homodimerizes or 
tetramerizes and binds ATP (Isohashi, Nakanishi et al. 1983; Isohashi, 
Nakanishi et al. 1983).  Expression of StARD15 has been localized to the 
liver, muscle, spleen and testes, but its enzymatic activity has only been 
demonstrated in the liver and kidneys.  Overall, little is known about the 
StARD15 protein and continuing molecular and functional studies are 
necessary to hash out the details of StARD15’s characteristics.   
RHOGAP Subfamily: StARD8, StARD12 & StARD13 
The human genome normally encodes over 50 RhoGAPs, of which 
three have START domains (Soccio and Breslow 2003).  Rho family of 
small GTPases signal in a variety of cell process like cell growth, 
morphogenesis, cell motility, cytokinesis, trafficking and cytoskeletal 
organization, as well as some more detrimental processes like tumor 
transformation and metastasis (Moon and Zheng 2003).  
StARD8 (DLC-3) 
StARD8, otherwise known as deleted in liver cancer 3 (DLC-3) is a 
tumor suppressor gene (Durkin, Ullmannova et al. 2007).  It is widely 
expressed, a characteristic that is reduced or lost in various cancers like 
lung, ovarian, kidney, prostate and breast.  There are two structures for 
StARD8, α, which is similar to its two other family members and β, which 
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lacks the N-terminal SAM domain.  Similar to other family members, 
StARD8 activates phospholipase C-δ-1 (PLCδ1) and has RhoGAP activity 
(Durkin, Ullmannova et al. 2007) 
 StARD12 (DLC-1) 
Also known as deleted in liver cancer 1 (DLC-1), StARD12 is a 
widely expressed tumor suppressor gene that is frequently homozygously 
deleted in primary hepatocellular carcinoma and breast tumors (Yuan, Zhou 
et al. 2003).  Many cancer cell lines, ranging from liver and breast to colon 
and prostate, have StARD12 expression deleted or lost, possibly due to 
promoter hypermethylation (Yuan, Zhou et al. 2003).   
StARD12 appears to have dual functions. First, it appears to interact 
with PLCδ1, activating phosphatidylinositol 4,5-bisphosphate (PIP2) 
hydrolyzing activity, raising intracellular Ca2+ levels rapidly (Homma and 
Emori 1995).  Second, its RhoGAP activity, specific for RhoA, enhances 
the conversion of RhoA from its active, GTP bound state to its inactive 
GDP bound state (Homma and Emori 1995).  GFP tagged localization 
studies have found StARD12 in the punctate structures of the PM and 
particularly in caveolae, which makes sense based on previous findings 
reporting interaction of StARD12 with caveolin-1 (Yamaga, Kawai et al. 
2008).  Homozygous knockout of StARD12 in mice leads to embryonic 
lethality at day 10.5 and heterozygotes are phenotypically normal (Durkin, 
Avner et al. 2005).    
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STARD13 (DLC-2)    
Like the other family members, StARD13 is also known as deleted 
in liver cancer 2 (DLC-2).  It too was found as a gene whose expression 
was decreased or absent in hepatocellular carcinomas.  Similarly, it encodes 
a RhoGAP specific for RhoA and Cdc42 (Nagaraja and Kandpal 2004).   
Localization studies have found it in the cytoplasm, mitochondria and lipid 
droplets (Ching, Wong et al. 2003).  Additionally, it has four isoforms 
(Ching, Wong et al. 2003).  Cellular over-expression increases cell 
proliferation, motility, transformation and RhoA activity and inhibits Ras 
signaling and Ras induced cellular transformation (Leung, Ching et al. 
2005).   
More work is needed to be done for all three members of the 
RHOGAP subfamily of StAR proteins to further elucidate functionality and 
importance of each of the proteins. 
StARD9 
StARD9 is one of the least studied StAR proteins.  It is found in 
sequence databases as a partial 1820 amino acid human coding sequence 
with a C-terminal StART domain and an undefined N-terminal (Soccio and 
Breslow 2003).  EST evidence hints that it is highly expressed in nervous 
tissue.  StARD9 exists in full length and exon 8 deleted forms (Halama, 
Grauling-Halama et al. 2006).  Much more work is needed to be done to 




























Figure 1.10 - Proposed Intracellular Localization of Various StAR Proteins: 
Depicted above is the proposed localization of many of the described StAR proteins known to 
date. 
StARD1- Has been shown to localize to the outer membrane of the mitochondria where it plays a 
role in steroidogenesis. 
StARD2 (PCTP) – Has been proposed to transport phosphotidylcholine from the ER to both the 
PM and the mitochondria. 
StARD3 (MLN64) - Has been localized to Late Endosomes where it plays a role in cholesterol 
sorting. 
StARD4 – Lacks a localization sequence and thus is thought to be cytoplasmic, helping to shuttle 
cholesterol from the PM and Endosomes to the ER. 
StARD5 – Also contains no localization sequence, but has been immunohistochemically stained 
and found to localize perinuculearly near the Golgi Apparatus. 
StARD6 – Is known to be expressed in testis and the CNS.  Little is known about its intracellular 
localization (not shown). 
StARD7 – Very little is known about StARD7 (not shown). 
StARD8 (DLC-3) – StARD8 has been shown to immunohistochemically localize to Focal 
Adhesions. 
StARD9 – Very little is known about StARD9 (not shown). 
StARD10 (PCTP-like) – Implied in phospholipid delivery to canilicular membranes, but never 
been shown (not shown). 
StARD11 (Cert) – GFP tagging studies show StARD11 in the cytoplasm and the Golgi. 
StARD12 (DLC-1) – GFP tagging experiments find StARD12 at the plasma membrane, 
specifically interacting with Caveolae. 
StARD13 (DLC-2) –StARD13 is thought to localize to lipid droplets and the mitochondria (not 
shown). 
StARD14 (BFIT) – little is known about the localization of StARD14 (not shown). 
StARD15 (CACH) - little is known about the localization of StARD15 (not shown). 
Abbreviations: ERC – Endoplasmic Recycling Compartment; ER – Endoplasmic Reticulum; LD – 
Lipid Droplet: PM – Plasma Membrane               
Dash lined = proposed routes or anchorings; Solid lines = known routes or anchorings. 
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Conclusion 
By binding lipid ligands, StART domains likely serve as 
transporters, shuttling lipids from subcellular compartments, or as lipid 
dependent regulators of cell signaling events.  This means that StAR 
proteins likely play roles in lipid metabolism, atherosclerosis, fertility, 
autoimmune disease and cancer, making them possible targets for drug 
therapy.  Although still in its nascent form, research into the StAR proteins 
proves to be promising for our understanding of these complicated 
processes.  To this end, this thesis focuses on work done to characterize the 













Chapter 2: Generation and Characterization of the StARD4 K.O. 
Targeted Knockout of the StARD4 gene 
 We knocked out the StARD4 gene in a manner that allows for 
complete knockout, tissue specific knockout and time dependent knockout 
using the strategy developed by Copeland and available from the NCI-
Fredrick website, http://recombineering.ncifcrf.gov/ (Liu, Jenkins et al. 
2003).   Through multiple steps of cloning and subsequent homologous 
recombination, loxP sites were introduced into the introns flanking exon 3 
of the StARD4 gene.  In the presence of cre-recombinase, this initiates 
excision of the exon 3, resulting in out of frame splicing of exon 2 to exon 
4, causing premature termination of transcription and ultimately a non-
functional StARD4 protein (Matthaei 2007).  Cre-recombinases expression 
can be driven by a variety of different promoters (i.e. CMV-cre – full 
knockout, Alb-cre – liver specific, Lys-cre – macrophage specific) allowing 
for generalized or tissue specific knockout of the StARD4 gene.  It is also 
possible to use an inducible promoter for the cre-recombinase or a viral 
delivery protocol to allow for StARD4 gene inactivation in a time 
dependent manner. 
 StARD4 is a 6 exon gene located on mouse chromosome 18 (Figure 
2.1) (Soccio, Adams et al. 2002).   The process of generating the StARD4 
knockout mouse was a complicated multi-step process.  To begin, a 
C57BL/6 background BAC clone (BacPac Resources, clone # RP23-
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46E14) was ordered that contained amongst many other genes, the StARD4 
genomic DNA.  Next, a targeting construct was created by excising the 
StARD4 genomic DNA from the BAC and inserting it into the MC1-TK 
plasmid that contains two LoxP sites.  As a positive selection marker, the 
downstream loxP sites on the plasmid also contained a Frt-PgK-Neo-Frt 
cassette.  Specifically, the upstream loxP site was placed 573 bp before 
exon 3 and the downstream Frt-PgK-Neo-Frt-loxP was placed 942 bp after 
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Figure 2.1 - Exonic Structure and Secondary and Tertiary  Structure of mStARD4  
A) StARD4 is a 272 amino acid protein encoded by 6 exons. Exons are represented as 
boxes with base pair lengths written inside.  Exonic sequences are white and the 5’ UTR 
is green. Introns are represented by lines connecting the boxes, with base pair lengths 
indicated above.  
B) Start Domain x-ray crystal structure.   StARD4 has four α-helices (blue) and nine 
β-strands (red) that form a u shaped capsule.  The C-terminal α-helix sticking upwards 
(αD), may open or unfold to allow lipid binding in the hydrophobic pocket locating 
internally.  The crested lipid binding pocket is the area affected by deletion of exon 3 and 





 Upon successful creation of the targeting construct, the next step was 
to recombine the targeted construct into mouse embryonic stem (ES) cells.  
Correctly targeted ES cells were identified by Southern Blotting, using 
EcoRI and EcoRV to digest the genomic DNA, with subsequent probing by 
5’ and 3’ probes designed by using the StARD4 sequence found on 
http://www.ensembl.org/index.html.  Only one correctly targeted mouse ES 
clone was found and this was used to inject mouse blastocysts to produce 























Figure 2.2 - Gene Targeting and Generation of a Conditional Knockout 
(Floxed) Allele of the StARD4 Gene.  
A) The targeting strategy employed to insert loxP sites on either side of exon 3 of 
StARD4.  First, a targeting vector was constructed by placing a Neo selectable 
marker flanked by Frt sites with a loxP site in intron 3. Next, a second loxP site was 
introduced in intron 2. B) PCR analysis to determine the presence of the floxed allele 
only found in heterozygotes and knockout mice (primer set AH.  A is a 5’ primer 
located in exon 2 and H is a 3’ primer located ~ 975bp downstream of exon 3). The 
Wt allele for AH is over 2000 bp and not normally seen in a conventional PCR. C) 
PCR analysis to determine the presence of the wild-type allele only found in 
heterozygotes and wild-type mice (primer set CH. Primer C is located in exon 3.  
Primer H is the same as above).  D) Western Blot analysis was performed on livers of 
12 week old StARD4 mice.  All samples were run in duplicate.  StARD4 is 
represented by a 23.5 KDa band.  E) β-Actin loading control for Western blot.  
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Figure 2.2 continued 
 
 
B)              C)    Wt     Het     K.O.   Wt     Het    K.O. PCR 
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Viability and Fertility of the StARD4 KO Mouse Line 
 Upon successful incorporation of the targeted construct into the 
mouse blastocysts and confirmation of germ-line transmission, mating 
between the chimera mouse containing the targeting construct and C57Bl6 
wild-type mice was undertaken.  The resulting heterozygous mice were 
bred to homozygosity and named Neo-floxed.  The Neo-floxed mice were 
then mated to the C57BL/6-ACT-FLPe homozygous mouse to excise the 
Frt-PgK-Neo-Frt cassette.  The progeny of this cross, named “Floxed”, 
were then bred to homozygosity.  The Floxed mice serve as the starting 
point for creation of the full knockout, tissue specific and time dependent 
knockout mice (Figure 2.3). 
 Next, to create a full knockout of the StARD4 gene, a Floxed 
homozygous mouse was mated to a C57BL/6 CMV-Cre homozygous 
mouse.  The Cre-recombinase, driven by the powerful CMV promoter, 
interacts with and removes all of the nucleotides between the two LoxP 
sites, creating a non-functional StARD4 gene and protein.   Brother-sister 
mating of the progeny yields deleted/null homozygous mice, which have 
been used throughout this thesis to evaluate the effects of the complete 
StARD4 knockout.   The absence or presence of StARD4 was verified at 
the mRNA level by PCR and the protein level by Western blotting (Figure 
2.1).   The genotype and gender of the offspring were also determined to 
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see if the KO affected the ratio of KO:Wt:Het and males: females.  The 























 Female Male 
Wt 14 14 
Het 25 20 








Litter Size (mean 
+/- S.D.) 
Male +/- x female +/+ 16 16 6.56 +/- 1.93 
Male +/+ x female +/- 11 11 6.36 +/- 3.17 
Male -/- x female -/- 5 5 7.02 +/- 1.35 
 
 
Table 2.1 - Mendelian Ratio of Mating to Homozygosity of the Neo Floxed 
StARD4 Gene.  
A) The ratio of WT/Het/KO of 102 mice born from the mating of two StARD4 mice 
heterozygous for the Floxed allele recombined by the cre-recombinase.  The progeny 
fit a normal Mendelian distribution for mice born under the expected 1:2:1 ratio of 
Wt:Het:KO (observed ratio = 28:45:29) .  When scrutinized with a chi square test, χ2 
= 1.922 with 2 degrees of freedom.  The two tailed p-value for this was 0.3826 
meaning that by conventional criteria, this difference is considered to be not 
statistically significant.  B) Both female and male heterozygous mutant mice were 
fertile and had similar litter sizes. 
 
  
A liver specific knockout was also created by mating the Floxed 
mouse with a C57BL/6 Alb-Cre mouse.  Although not studied in this thesis, 
this mouse was made because it will allow others to study the role of liver 
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StARD4 Conditional/Full Knockout Strategy 
 
Figure 2.3 - Mating Strategy in Generation of the StARD4 Knockout. 
Chimera mice were mated to C57Bl6 to generate Neo heterozygotes which were then 
brother-sister mated in attempt to generate Neo homozygotes. The Neo heterozygotes 
were also mated to the ACT-FLPe transgenic mice to remove the FrtNeoFrt cassette.  
These Floxed heterozygotes were brother-sister mated in an attempt to generate 
Floxed homozgotes. The Floxed homozygotes were mated to CMV-Cre transgenic 
mice to remove exon 3 and to generate Null/Deleted heterozygotes. These Null 
heterozygotes were brother-sister mated in an attempt to generate Null homozygotes. 
Brother-sister matings resulted in the normal Mendelian ratio for breeding of mouse 
lines with average liter size between 6-7 pups.  Teal squares represent exons, 
triangles represent loxP sites, a white square represents the FrtNeoFrt cassette and 







Expression of StARD4 in Various Tissues 
 To determine sites of StARD4 expression, I analyzed StARD4 
mRNA and protein levels in various tissues.  Three individual mice were 
sacrificed, various organs collected, RNA isolated and qPCR run for 
StARD4 expression.  StARD4 is most highly expressed in the liver and 
macrophages, followed by the kidney and lung.  Expression of StARD4 is 








































































Figure 2.4 Expression Level of StARD4 in Various Tissues as Confirmed by qPCR.  
Tissues from 3 male WT mice were collected, RNA isolated and tested for expression of 
StARD4 RNA expression by qPCR.  All samples are normalized to GapDH and shown as 
relative ratios.  Std is represented by lines above the bar graphs. 
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Initial Screening of the StARD4 Knockouts 
 I initially determined a growth curve for the StARD4 knockout mice 
from 4 to 12 weeks of age.  At 12 weeks, mice were sacrificed to determine 
levels of total cholesterol, cholesterol ester, free cholesterol, triglyceride 
and glucose as well as plasma lipoprotein levels.   In addition, at autopsy, 
organs were evaluated for pathology at both the gross and microscopic 
levels.   
 At 12 weeks, both male and female knockout mice, fed a standard 
chow diet, showed a decrease in body weight compared to wild-type 
littermates (Figure 2.4).  The change was more evident in male mice in 
which the weight difference was significant, starting at 5 weeks of age, 
whereas in female mice, a significant difference was only seen at 12 weeks 



























































Figure 2.5 - Growth Curve of StARD4 Knockout Mice 
StARD4 mice (Wt/Het/KO) from 4 weeks of age after weaning, until 12 weeks of 
age, fed a chow diet. Weights of mice were recorded weekly.  Weights are 
represented as means with the Std indicated by the vertical lines. 












Table 2.2 - Weights of StARD4 Knockout Mouse & Wild-type Littermate, Week 4-12 
 
Week 4 5 6 7 8 9 10 11 12 
Female 


























































p-value 0.21 0.18 0.45 0.35 0.52 0.30 0.24 0.53 0.02 



























































p-value 0.22 0.01 0.01 0.07 0.003 0.05 0.04 0.02 0.03 
 
All values are means +/- Std.  








To evaluate the physiological significance of the weight difference, 
at 12 weeks of age, measurements were also made of length (rump to head) 
and the size of the feet and hands.  Both male and female knockout mice 
were shorter and had smaller feet and hands.  This suggests that the 
knockout mice were not failing to just gain weight, but rather have a 
generalized growth abnormality.  Using weight and length measurements, 
BMI was calculated and there was no difference between StARD4 
knockout and wild type mice (Figure 2.6) 
 
 Weight (g) Height  BMI (g/mm2) 
Male                    Wt 
n = 14 
28.0 +/- 2.0 9.3 +/- 0.2 (3.1 +/- 0.1) x 10-3 
 
K.O. 
n = 9 
26.0 +/- 1.7 8.9 +/- 0.3 (3.3 +/- 0.1) x 10-3 
 
p-value 0.034 0.001 0.101 
Figure 2.6 - Length Measurements of StARD4 Knockout Mice 
StARD4 mice (Wt/KO) at 12 weeks of age, fed a chow diet. Heights of mice were 
recorded with mice euthanized and laid flat on their backs.  Lengths are indicated in 
cm. n=number of mice. 
 
The weights of various organs were also analyzed including liver, kidney, 
heart, spleen, lung and epididymal fat pads.  In knockout mice, male liver, 
kidney and hearts and female hearts were significantly lighter than in wild 
type mice, but all were in proportion to the overall decrease in weight and 
none stood out as being especially affected (Table 2.3).   
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Table 2.3 - Organ Weights of StARD4 Mice at 12 Weeks of Age 
          Liver (g)        Kidney (g)        Heart (g)        Spleen (g)        Lung (g)        Adipose (g) 
Female  
Wt 
n = 11 
 






0.14 +/- 0.09 
 
0.24 +/- 0.19 
 
0.11 +/- 0.03 
K.O. 
n = 10 
 
0.77 +/- 0.06 
 
0.13 +/- 0.03 
 
0.10 +/- 0.01 
 
0.09 +/- 0.03 
 




        0.136 
 
         0.358 
 
         0.040 
    
        0.107 
 
        0.244 
 
           0.609 
Male  
Wt 
n = 16 
 
1.12 +/- 0.14 
 






0.16 +/- 0.04 
 
0.19 +/- 0.05 
K.O. 
n = 10 
 
0.98 +/- 0.31 
 
0.15 +/- 0.05 
 
0.11 +/- 0.03 
 
0.08 +/- 0.04 
 
0.15 +/- 0.04 
 
0.16 +/- 0.05 
p-value  
       0.019           
 
        0.007 
 
      0.00004 
 
         0.656 
 
        0.094 
 
           0.237 
 
All values are means +/- Std. 
n = number of mice. 
* indicates a p-value < 0.05. 
 
 
Pathology of StARD4 Knockout Mice 
 
 A complete pathological examination was performed on StARD4 
knockout mice and their wild-type littermates by the Tri-institutional Core 
Facility located in the Memorial Sloan Kettering Cancer Center Pathology 
Department.  No anatomical or histological differences between StARD4 
knockout and wild type mice  were found in any of the organs analyzed 
including;  brain, heart, lung, spleen, liver, gallbladder, stomach, 
deudenum, jejunum, ileum, colon, cecum, thymus, tongue, kidney, 
esophagus, pancreas, renal lymph nodes, salivary glands, brown fat, adrenal 
glands, sciatic nerve, spinal chord, thyroid glands.  In addition, no 
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differences were found in blood chemistries as well as blood count 
including: alkaline phosphotase, alanine aminotransferase, asparagine 
aminotransferase, γ-Glutamyl Transpeptidase, albumin, globulin, creatinine, 
phosphorous, chloride, potassium, sodium, albumin to globulin ratio, BUN 
to creatine ratio, osmalality, anion gap, red blood cells, white blood cells, 
neutrophils, lymphocytes, monocytes, eosinophils and platelets. 
Plasma Cholesterol, Triglycerides and Glucose Concentrations 
 At 12 weeks of age, plasma lipids were compared between StARD4 
knockout and wild type mice and no significant differences were found in 
concentraions of cholesterol, HDL, triglycerides, glucose, free cholesterol 















Table 2.4 - Plasma Lipid Concentrations of StARD4 Mice at 12 Weeks of Age Fed a      
Chow Diet 
 





        Wt                              KO 
Male 
 
        Wt                           KO 
Total Chol.     (mg/dl)  
n= 
 
   62 +/- 12                     63 +/- 2 
          9                                 9  
 
    64 +/- 13                 68 +/- 11 
          12                             9 
 
HDL                (mg/dl)  
n= 
    25 +/- 4                      25 +/- 5 
           9                                8  
 
     37 +/- 8                  32 +/- 8 
          10                            8 
 
Non – HDL    (mg/dl) 
              n=  
(calculated)  
    37 +/- 8                      38 +/- 3  
         9                                  8 
                                   
     27 +/- 5                   36 +/- 3 
Free Chol.      (mg/dl)   
n= 
   10 +/- 3                      11 +/- 3 
        13                               11 
             
    21 +/-10                   17 +/- 4 
         15                              9 
 
Chol. Ester     (mg/dl)   
n= 
  50 +/-10                       53 +/- 3 
         9                                  9 
 
    46 +/- 15                  56 +/- 12 
          12                             9 
 
Triglycerides  (mg/dl)  
         n= 
  21 +/- 6                        27 +/- 8 
       10                                 12 
 
    30 +/- 8                     35 +/- 8 
          11                            14 
 
Glucose           (mg/dl)  
   n=  
138 +/- 24                    116 +/- 20
       11                                  8 
 
   160 +/- 36                163 +/- 28 
          11                              9 
 
n = number of mice per sample. 
All P-values were not significant. 
 
Hepatic Lipid Concentrations 
 
 Since StARD4 expression is highest in liver and in primary 
hepatocytes, it is logical to examine the effect of the StARD4 knockout on 
liver lipids (Rodriguez-Agudo, Ren et al. 2008).  Furthermore, it has been  
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published that StARD4 over expression in primary mouse hepatocytes has 
led to increase cholesterol ester synthesis (Rodriguez-Agudo, Ren et al. 
2008).  At 12 weeks of age, hepatic lipids were extracted by the Folch 
method from StARD4 knockout and wild type mice and total cholesterol, 
free cholesterol, cholesterol ester, and triglyceride levels were determined, 
but no significant differences found (Table 2.5).   





        Wt                              KO 
Male 
 
        Wt                           KO 
Total Chol.(mg/g)   
         n= 
 
  2.8 +/- 0.5                   2.4 +/- 0.4 
          8                                 9  
 
  1.6 +/- 0.3                2.1 +/- 0.7 
        10                              8 
 
Free Chol.  (mg/g) 
     n= 
  2.2 +/- 0.5                   1.9 +/- 0.4 
         8                                  9 
 
  1.2 +/- 0.3                1.5 +/- 0.6 
       10                               8 
 
Chol. Ester(mg/g)   
n= 
 0.6 +/- 0.4                    0.54 +/- 0.3 
         8                                    9 
 
   0.4 +/- 0.1               0.4 +/- 0.2 
         10                             8 
 
TG              (mg/g)  
n= 
 14.2 +/- 4.9                   12.2 +/- 4.6 
         7                                     8 
 
   7.9 +/- 3.5                7.4 +/- 2.5 
          10                             8 
 
 All values are means +/- std.   
 n = number of mice per sample. 
All P-values were not significant.  
 
Gallbladder Bile Concentrations 
 Gallbladder bile was extracted from 12 week old StARD4 knockout 
and wild-type mice and concentrations of cholesterol, phospholipids and 
bile acids analyzed.  Female knockout mice showed a significant reduction 
in both total cholesterol and phospholipids, whereas in males there was no 
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significant difference in bile concentration (Table 2.6).  The results in 
females are compatible with the hypothesis that StARD4 plays a role in 
delivering cholesterol to the hepatocyte canalicular membrane for excretion 
into bile. 
 





        Wt                              KO 
Male 
 
       Wt                              KO 
Total Chol.      (mg/dl)  
    n= 
 190 +/- 50                    135 +/- 64*     
        10                                 10 
 
 186 +/- 59                   161 +/- 88 
        15                                11 
 
Phospholipids (mg/dl)   
n= 
2065 +/- 573                1576 +/- 591*  
          13                                13 
 
1446 +/- 256              1532 +/- 424 
         15                                9 
 
Bile Acids        (mg/dl)   
n= 
    94 +/- 35                      76 +/- 6        
          9                                 11 
 
   43 +/- 15                    46 +/-16 
        15                               10  
 
 
All values are means +/- Std.   
n = number of mice per sample.  
 
 
Glucose Tolerance (IPGTT Test) 
 Aside from lipid measurements, the StARD4 mice were examined 
for glucose metabolism by and intraperitoneal glucose tolerance test 
(IPGTT) three to five days before sacrifice at 12 weeks of age.  After 
injecting a glucose bolus of 2g/kg, plasma glucose levels were determined 
at 0, 15, 30, 60 and 120 minutes.  This test did not reveal any difference in 
glucose tolerance between StARD4 knockout and wild-type littermates 
(Figure 2.7). 
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Figure 2.7 - Intraperitoneal Glucose Tolerance Test of StARD4 Mice 
11.5 week old StARD4 knockout mice and their wild-type littermates were injected 
with a 2g/kg of body weight bolus of glucose and glucose measurements were made 
at the above indicated times.  All values indicated averages of the indicated n.  Std 










Food Intake of StARD4 Mice, Week 6-8 
To better understand the weight difference between StARD4 
knockout and wild-type mice, 5 male mice of each group were single caged 
at 6 weeks of age and food intake and body weight recorded daily for two 
weeks.  At 8 weeks, a trend to decreased body weight was observed in the 
StARD4 knockouts and the weight difference between knockout and wild 
type mice became significant in the last 3 days of this period.  However, 
there was no significant difference in food intake or food intake per body 
weight during this period (Figure 2.8).  These observations suggest that the 
decreased body weight of StARD4 knockouts is not due to decreased 















































































Figure 2.8 - Food Intake Experiment on StARD4 Mice, Week 6-8 
Five 6 week old StARD4 mice and five 6 week old wild-type mice’s food intake and 
body weight were recorded daily at 4pm for two weeks straight.  Although weights 
seem to diverge as previously recorded, reaching and then maintaining significance 
from day 11 onwards, the corresponding food intake did not seem to be responsible 
for the change. A) Body Weight.  B) Food Intake.  C) Food Intake / Body Weight.   
indicates a p-value < 0.05 
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High Fat Diet Study and Dual Energy X-Ray Absorptiometry (DEXA) 
Scan 
To better understand the mechanism underlying the StARD4 weight 
phenotype, the 10 mice used above for the food intake study, underwent 
DEXA scan for body composition at 8 weeks of age, were fed a high fat 
diet (60% of calories from fat) for 12 weeks, and rescanned at 20 weeks of 
age.  Weights were determined weekly and on the high fat diet the StARD4 
knockout mice caught up to the wild type mice and no difference in weight 
was observed through to week 20 (Figure 2.9).  The DEXA scans at 8 and 
20 weeks showed no difference between StARD4 knockout and wild type 
mice in lean mass, fat mass, the ratio of lean to fat mass and bone mineral 

























Figure 2.9 - High Fat Diet Experiment on StARD4 Mice, Week 6-8 
Five 8-20 week old StARD4 mice and 5 wild-type littermates were fed a 60% high 
fat diet.  Their weights were recorded weekly starting at week 6, 2 weeks before 
feeding began.  There appears to be no difference in weight phenotype of the 





































Figure 2.10 - Dexa Scan of StARD4 Mice at Week 8 
Five 8 week old StARD4 mice and 5 wild-type littermates were subjected to a Dexa 
Scan to elucidate their body and bone composition. There appears to be no difference 
in lean versus normal fat or between bone mineral content and density of knockout 










































Figure 2.11 - Dexa Scan of StARD4 Mice at Week 20 After 12 Weeks of High 
Fat Diet Feeding 
Five 8-20 week old StARD4 mice and 5 wild-type littermates were fed a 60% high 
fat diet.  At week 20, a day before sacrifice, mice were subjected to a Dexa Scan to 
elucidate their body and bone composition. There appears to be no difference in lean 
versus normal fat or between bone mineral content and density of knockout and wild-






Microarray of StARD4 Mice 
 The effect of StARD4 knockout on liver gene expression was next 
examined, by extracting RNA from the livers of 4 StARD4 knockout and 4 
wild-type mice at 12 weeks of age.  Each of these RNA samples were 
analyzed separately.   The RNA was analyzed using the Illumina Mouse-
Ref-8 array, which evaluates expression of over 23,000 genes. 
 The data was analyzed with GeneSpring GX 10 software.  As a first 
step, I determined whether the StARD4 knockout and wild type data 
differed in their output readings (i.e. were there differences that can linked 
back to differences in plate reading, fluorescence level, etc.).  If this were 
the case, it is necessary to normalize the 2 data sets so that they could be 
compared.  Since this was not the case I did not apply normalization prior 
to comparison of each sample group expression profile (Figure 2.12). 
 
Figure 2.12 - Non-normalized Data of Microarray of StARD4 Mice 
RNA from Liver of 12 week old mice analyzed with the Illumina Mouse-Ref-8 
gene chip.  Picture above represents all eight samples with no normalized 
expression patterns. 
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  Expression profiles were then compared between StARD4 knockout 
and wild type mice.  I found only 2 genes that showed a 2-fold difference in 
expression; LCN2 & HAMP.  There were 10 genes with greater than a 1.5-
fold difference in expression, 20 genes greater than 1.4-fold, 38 genes 
greater than 1.3-fold, 84 genes greater than 1.2-fold and 1,371 genes greater 
than 1.1-fold.  Comparing expression of these genes between StARD4 
knockout and wild type mice by an unpaired t-test revealed no significance 
difference between the genotypes at the P<0.05 level for any expression 
fold change above 1.1.   When fold change was lowered to low level fold 
changes, such as 1.036, was a list of 288 genes extracted that had 
significant changes, P<0.05 (these genes also survived basic multiple 
testing corrections otherwise known as Bonferroni Hochberg false 
discovery rate testing). Given the putative role of StARD4 in intracellular 
cholesterol transport, surprisingly we did not find expression differences 
between the genotypes in genes known to play roles in hepatic cholesterol 
metabolism including: ABCG5/8, SREBP1a/1c/2, HMCGR, Cyp7α1, 
Cyp27α1, MDR2, NPLC1, LDLR, LXR, FXR, PPARα, BSEP,  Insig1/2, 
ApoA1, ApoB and other StAR proteins (Figure 2.13).   
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Figure 2.13 - List of Genes Who’s Fold Change is Greater Than 1.391 
Genes found to have fold change expression above 1.391.  Many of the genes here 




A few of the genes involved in cholesterol transport were examined for 
expression changes to verify the microarray data.  These genes included 
StARD5, StARD1, MLN64, NPC1, NPC2, Cav-1, Cav-2.   None of the 


































0% Cholesterol - K.O.
 
Figure 2.14 - RNA Expression Levels of Intracellular Cholesterol Transporters  
Five male mice at 12 weeks of age fed a chow diet were sacrificed, their livers 
extracted and the RNA expression of the above genes were determined via qPCR.   
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 The list of all genes extracted by the microarray study was then 
imported into Ingenuity and the Broad Institute’s GSEA (gene set 
enrichment analysis) program to analyze for the possibility of linking genes 
together by network, whose otherwise small fold change might go 
undetected as insignificant.   Ingenuity network analysis pulled out one 
enriched gene called HGF or hepatic growth factor.  It had a 1.1 fold 
change above baseline and its expression is associated with a decrease in 
lipid droplets formation in developing mice (Tahara, Matsumoto et al. 
1999).   This is interesting because it has been reported that StARD4 
overexpression in primary mouse hepatocytes leads to increase in lipid 
droplet formation (Rodriguez-Agudo, Ren et al. 2008).  One would suspect 
decreased lipid droplet formation in a StARD4 knockout and the HGF 
expression increase seems to correlate with this hypothesis that StARD4 
knockout would decrease lipid droplet formation.  
GSEA analysis pulled out two lists of genes.  One was for 
glutathione metabolism, while the other was for xenobiotic metabolism.   







Table 2.7 - List of Genes Enriched by GSEA Analysis 











































0.2% Lovastatin and 0.5% High Cholesterol Feeding Study  
Although a phenotype of decreased bile secretion in females of the 
StARD4 mice was found, no overall plasma lipid phenotype, a major 
marker for studying the phenomenology of atherosclerosis heart disease, 
was found.  To study this further, two diet studies were undertaken to 
determine differences in the lipid profile.  The diets were implemented as 
follows.  Wild-type and knockout mice, male and female, were started at 
week 6 on a 0% cholesterol diet and then switched at week 7 to either a 
0.2% lovastatin (0% cholesterol) enriched diet or a 0.5% high cholesterol 
diet.   At week 8, the mice were sacrificed for analysis.   
The first step in analysis was to check for the effect each diet had on 
StARD4 mRNA expression and protein levels.  RNA was extracted from 6 
wild-type mice and mRNA expression of StARD4 was measured via qPCR. 
Significant increase in StARD4 message was found in mice fed a 0.2% 
lovastatin diet, while StARD4 expression levels only increased modestly in 
mice fed a 0.5% cholesterol diet.    
Next, protein was extracted from 2 individual wild-type mice from 
each diet group, and protein levels were analyzed via western blotting for 
StARD4.  Concordant with the RNA work, StARD4 protein levels of wild-
type mice on the 0.2% lovastatin diet were elevated when compared to both 
the 0% cholesterol control and 0.5% cholesterol diets. 
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StARD4 Expression in Wildtype Mouse Livers at 8 











































 0% Chol    0.2% Lova     0.5% Chol.  





Figure 2.15 - Wild-type RNA Expression and Protein Levels of StARD4 on 
Three Diets 
Mice at 6 weeks of age were fed 0.0% cholesterol diets for one week and then 
switched to either a 0.0% cholesterol diet, 0.0% cholesterol + 0.2% lovastatin diet or 
to a 0.5% cholesterol diet.  At 8 weeks of age, mice were sacrificed.  Then StARD4 
expression and protein levels were delineated by qPCR or by western blotting.  For 
RNA work n=6 and for protein all samples were analyzed in duplicate. 
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Plasma Lipid Concentrations on the 0.2% Lovastatin Diet 
At 8 weeks of age, plasma lipids were compared between StARD4 
knockout and wild type mice on the 0.2% lovastatin diet and no significant 
differences were found in levels of cholesterol, HDL, non-HDL, free 
cholesterol, cholesterol esters and triglycerides (Table 2.8).  
Table 2.8 - Plasma Lipid Concentrations of StARD4 Mice at 8 Weeks of Age Fed a 







        Wt                              K.O. 
Male 
 
        Wt                           K.O. 
Total Cholesterol 
         (mg/dl)     n= 
 
   53 +/- 12                      50 +/- 16 
         12                                12  
 
    73 +/- 12                 75 +/- 20 
         12                             9 
 
HDL 
(mg/dl)     n= 
    26 +/- 8                        27 +/- 7  
           8                                  7 
 
    42 +/- 15                  42 +/- 10  
         12                              9 
 
Non - HDL 
        (mg/dl)      n=  
(calculated) 
   27  +/- 4                         23 +/- 9 
           8                                  7 
 
    31 +/- 3                    33 +/- 10 
          12                              9 
Free Cholesterol 
(mg/dl)     n= 
    14 +/- 4                         13 +/- 6 
         12                                  12 
 
   19 +/- 4                      21 +/- 4 
        12                                9 
 
Cholesterol Ester 
(mg/dl)     n= 
    39 +/- 10                      33 +/- 17 
         12                                  12 
 
   54 +/- 9                      45 +/- 18 
        12                                9 
 
Triglycerides 
         (mg/dl)     n= 
   34 +/-17                         35 +/-14 
        12                                   12 
 
  39 +/- 12                     35 +/- 14 
       12                                 9 
 
All values are means All values are means +/- Std.   
n = number of mice per sample.  







Hepatic Lipid Concentraions on the 0.2% Lovastatin Diet. 
 
 At 8 weeks of age, hepatic lipids were extracted by the Folch method 
from StARD4 knockout and wild type mice and total cholesterol, free 
cholesterol, cholesterol ester, and triglyceride levels were determined, but 
no significant differences found (Table 2.9). 
Table 2.9 - Hepatic Lipid Concentrations of StARD4 Mice at 8 Weeks of Age Fed a 





        Wt                              K.O. 
Male 
 
        Wt                           K.O. 
Total Chol.(mg/g)   
         n= 
 
  2.4 +/- 0.5                   2.9 +/- 0.9 
        11                                11  
 
  2.8 +/- 0.6                2.4 +/- 0.7 
        12                              7 
 
Free Chol.  (mg/g) 
     n= 
  2.0 +/- 0.8                   2.6 +/- 0.7 
        10                                10 
 
 2.3 +/- 0.8                 1.6 +/- 0.5 
       10                               7 
 
Chol. Ester(mg/g)   
n= 
 0.4 +/- 0.4                    0.4 +/- 0.3 
       10                                 10    
 0.48 +/- 0.4              0.76 +/- 0.5 
         10                              7 
 
TG              (mg/g)  
n= 
 13 +/- 5.2                      11 +/- 5.2 
      11                                  11 
 
 9.3 +/- 3.7                 7.7 +/- 3.4 
       12                               7 
 
All values are means +/- Std.   
n = number of mice per sample. 









Plasma Levels on the 0.5% Cholesterol Diet 
 At 8 weeks of age, plasma lipids were compared between StARD4 
knockout and wild type mice on a 0.5% cholesterol diet and no significant 
differences were found in levels of HDL, triglycerides, free cholesterol and 
triglycerides.  However, there was a significant decrease in total 
cholesterol, LDL and cholesterol ester in female mice at week 8 (Table 
2.10). 
Table 2.10 - Plasma Lipid Concentrations of StARD4 Mice at 8 Weeks of Age Fed a 






        Wt                              K.O. 
Male 
 
        Wt                           K.O. 
Total Chol.   (mg/dl) 
     n= 
 
  101 +/- 17                    83 +/- 19 * 
         12                               12 
    88 +/- 15                  90 +/- 20 
         12                              9 
HDL              (mg/dl)  
n= 
  28 +/- 6                        23 +/- 4 
        7                                   9 
    35 +/- 8                     34 +/- 4 
         10                               5  
LDL              (mg/dl)   
n= 
  32 +/- 18                      17 +/- 8 * 
        7                                   9 
    23 +/- 9                     18 +/- 5 
         10                               5 
VLDL           (mg/dl)   
n= 
  18 +/- 9                        14 +/- 5 
        7                                   9 
    9 +/- 6                        7 +/- 3 
       10                                5 
Free Chol.    (mg/dl)   
n= 
  18 +/- 5                        15 +/- 4 
       12                                 12 
    19 +/- 3                     19 +/- 5 
         12                               9 
Chol. Ester   (mg/dl)   
n= 
  83 +/- 14                    69 +/- 17 * 
        12                               12 
   69 +/- 13                    72 +/- 16 
         12                               9 
TG                 (mg/dl)  
         n= 
  24 +/- 8                      24 +/- 8 
       12                                12 
  26 +/- 4                       27 +/- 5 
        12                                9 
 
All values are means +/- Std.   
n = number of mice per sample.  
* = p-value < 0.05  
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Hepatic Lipid Levels on the 0.5% Cholesterol Diet 
 
 At 8 weeks of age, hepatic lipids were extracted by the Folch method 
from StARD4 knockout and wild type mice and total cholesterol, free 
cholesterol, cholesterol ester, and triglyceride levels were determined, but 
no significant differences found (Table 2.11) 
Table 2.11 - Hepatic Lipid Concentrations of StARD4 Mice at 8 Weeks of Age Fed a 





        Wt                              K.O. 
Male 
 
        Wt                           K.O. 
Total Chol.(mg/g)   
         n= 
 
  13 +/- 4.8                      13 +/- 5.5 
        8                                    9 
   8.5 +/- 2.6               8.0 +/- 4.5 
          8                              8 
Free Chol.  (mg/g) 
     n= 
  4.9 +/- 1.2                    4.2 +/- 2.1 
         8                                   9 
   3.1 +/- 1.1               3.0 +/- 0.8 
          8                              8 
Chol. Ester(mg/g)   
n= 
 8.0 +/- 4.6                    8.6 +/- 5.2 
         8                                   9  
  5.4 +/- 2.2                5.0 +/- 4.6 
          8                              8 
TG              (mg/g)  
n= 
 15 +/- 3.9                     16 +/- 7.3 
      8                                    9 
  13 +/- 7                    8.6 +/- 2.7  
        8                                8 
All values are means +/- Std.   
n = number of mice per sample.  








RNA Expression of Select Genes Known to be Involved in Intracellular 
Cholesterol Dynamics and Metabolism. 
Some of the genes that are known to play a role in intracellular cholesterol 
transport or metabolism, like StARD5, MLN64, NPC1, NPC2, LDLR and 
HMGCR, were validated for their expression levels on the 0% cholesterol, 
0.2% lovastatin and 0.5% cholesterol diets.  For each sample, five 
individual male mice were sacrificed at week 8 and RNA was extracted 
using standard TRIzol isolation.  Interestingly, after a deeper analysis, it 
was found that NPC1, a gene found to be decreased 2.5 fold in the StARD4 
knockout, was not one of the annotated genes present in the Illumina 
Mouse-Ref8 gene array.   There were also significant increases in 
expression found for StARD5 on both the 0.2% lovastatin diet and the 0.5% 











































0% Cholesterol - KO
0.2% Lovastatin - WT
0.2% Lovastatin - KO
0.5% Cholesterol - WT
0.5% Cholesterol - KO
 
Figure 2.16 - RNA Expression Levels of Intracellular Cholesterol Transporters on 
Various Diets 
Mice at 6 weeks of age were fed 0.0% cholesterol diets for one week and then switched 
to either a 0.0% cholesterol diet, 0.0% cholesterol + 0.2% lovastatin diet or to a 0.5% 
cholesterol diet.  At 8 weeks of age, mice were sacrificed.  Then RNA was extracted from 
livers and expression determined by qPCR. 
 
Cholesterol Efflux from Bone Marrow Primary Macrophages 
 As there are two important sites implicated in the development of 
atherosclerosis, the liver since it is the major organ of cholesterol synthesis 
and the endothelial space where the actual plaque builds and ultimately 
ruptures, it was next prudent to check processes involved in the endothelial 
space of the atherosclerotic model.  One of these processes and perhaps the 
best understood and most studied, is the process of effluxing cholesterol 
from macrophages to HDL particles, a part of the RCT pathway (Tall, 
Yvan-Charvet et al. 2008).  This process is important, as it is thought 
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capable of removing cholesterol from the site of plaque formation, 
ultimately reversing the deleterious effects of high plasma cholesterol and 
is a major area of interest for drug development.  To this end, in 
collaboration with one of the leading laboratories in macrophage efflux, 
Alan Tall’s laboratory at Columbia University, efflux experiments were 
performed from bone marrow primary macrophages extracted from both 
wild-type and StARD4 knockout mice.   The experiment was run under two 
separate conditions and with two different acceptors to test the two efflux 
channel proteins involved in cholesterol efflux.  The conditions were with 
and without the LXR agonist, T0903170, which is known to stimulate 
cholesterol efflux (Tall, Yvan-Charvet et al. 2008).  The two acceptors were 
HDL2 and ApoA-1.  HDL2 accepts its cholesterol from the protein channel 
ABCG1 and ApoA-1 from ABCA1.  Unfortunately, no differences were 
found between the StARD4 knockout and the wild-type macrophages in 
























Figure 2.17 Cholesterol Efflux in Primary Bone Marrow Macrophages to HDL2 and 
ApoA-1 With and Without the LXR Agonist T093170 
Mice at 8 weeks of age were fed a chow diet, sacrificed and their bone marrow 
macrophages isolated for efflux assays.  Macrophages were plated 4x and either exposed 
to the LXR agonist T093170 or not.  Then the rate of efflux of cholesterol was measured 
to the acceptor HDL2 or ApoA-1. 
 
Filipin Stain 
 It has been shown in the Breslow lab that StARD4 knockdowns in 
HepG2 cells can lead to a rather profound phenotype.  As the PM is the 
main site for storage for intracellular cholesterol (Simons and Ehehalt 
2002), knockdowns appear to have a marked localization of cholesterol in 
the PM as shown by filipin staining.  For comparison, the wild-type 
controls appear to have cholesterol all over the cytoplasm, indicative of its 
shuttling, presumably by StARD4.  To verify this, primary hepatocytes of 
StARD4 knockouts have been isolated, cultured and then stained with 
filipin, in a manner similar to the cell culture work.  Unfortunately, the 
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drastic change between PM cholesterol and intracellular cholesterol seen in-
vitro is not as striking in the primary hepatocyte model used from StARD4 





Figure 2.18 - Filipin Staining of Primary Mouse Hepatocytes  
Primary hepatocytes from both StARD4 knockout and wild-type mice were 
isolated, seeded and ultimately stained for free cholesterol using filipin staining.  
Unlike the in-vitro model, there appeared to be no drastic change with localization 
of cholesterol in the plasma membrane knockout primary hepatocytes. Filipin 
stain is seen in white in the photo delineating the patterning of free cholesterol 




Crossing the StARD4 K.O. onto the LDLR K.O. Background 
 To elucidate the possible effect StARD4 has on the progression or 
regression of atherosclerosis, StARD4 knockout mice were crossed onto the 
atherosclerotic-susceptible B6.LDLR K.O. background.  After weaning at 4 
weeks of age, double knockout mice and their wild-type littermates were 
fed a low-fat, low-cholesterol, semi-synthetic diet (called the AIN76-A, 
Clinton Cybulsky diet) for 16 weeks (Teupser, Persky et al. 2003).  The 
animals were sacrificed at week 20 and aortic root cross sectional lesion 
areas were compared between wild-type and knockout StARD4 mice.  
Comparisons were also made of the body weight and plasma lipids similar 
to what was done for the mice on a chow diet.   
Plasma Lipid Concentrations on the 0.02% Cholesterol Diet 
 StARD4 K.O. effect on plasma lipids was next tested on the LDLR 
K.O. background on a 0.02% cholesterol diet.  Plasma was collected at 20 
weeks of age, calorimetric assays were conducted and there were no 
significant differences found between wild-type and knockout mice, in their 
overall levels of total cholesterol, HDL, LDL and VLDL.  However, there 






Table 2.12 - Plasma Lipid Concentrations of StARD4 Mice at 20 Weeks of Age Fed 







        Wt                              K.O. 
Male 
 
        Wt                           K.O. 
Total Chol.   (mg/dl)  
             n= 
 
  417 +/- 179                 402 +/- 193
         13                                10  
 406 +/- 163               464 +/- 145 
         8                                 8 
HDL              (mg/dl)  
n= 
  39 +/- 10                      40 +/- 12 
       13                                  10 
  58 +/- 22                    52 +/- 13 
        8                                 8 
LDL              (mg/dl)   
n= 
 127 +/- 55                    150 +/- 88 
        13                                 10 
 200 +/- 85                 263 +/- 103 
         8                                8 
VLDL           (mg/dl)   
n= 
 154 +/- 91                      93 +/- 46 
        13                                 10 
  51 +/- 31                    52 +/- 40 
        8                                 8 
TG                 (mg/dl) 
        n= 
  209 +/- 91                  124 +/- 57* 
        13                                 10  
 134 +/- 69                 147 +/- 71 
         8                                8 
All values are means +/- Std.   
n = number of mice per sample.  
* = p-value < 0.05 
 
 
Atherosclerosis Lesions in StARD4 Mouse Aortas on the 0.02% 
Cholesterol Diet 
 Percent atherosclerotic lesion in StARD4 knockout mouse fed a 
0.02% cholesterol diet was checked. To quantify cross-sectional lesion area 
in the aortic root, heparinized flushed hearts were embedded in OCT.  
Cutting was begun immediately once the valves were viewed and sections 
were saved on glass slides every 12μm in thickness. Sections were stained 
with oil red O and lesion area quantified by the level of staining of the 
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internal elastic lamina in every fourth section.  For any mouse in which 
atherosclerosis was assessed, aortic root lesion area was the average of 5 of 
these sections.  Unfortunately, no significant changes were found in the 































Figure 2.19 - Atherosclerotic Lesion Area in StARD4 Knockout Mice Aortas 
StARD4 knockout mice and their wild-type littermates were fed a 0.02% AIN76a 
cholesterol diet.  Atherosclerotic lesions were calculated as described above and 
no significant changes were found in the development of atherosclerosis in the 











 This chapter describes my attempts to study the physiological role of 
StARD4 in-vivo through the creation of a StARD4 knockout mouse model 
and the subsequent experiments completed to characterize the knockout.  
This work revelead some findings that can hopefully be used to build upon 
for future experimentation.   StARD4 knockout mice do show a weight 
difference and although not seemingly directly linked to metabolism, there 
are potential other avenues discussed in later sections that can be explored 
to analyze StARD4’s role in this context.  StARD4 also showed changes in 
bile in female knockout mice that link its role to cholesterol excretion 
through the biliary system, a key component of the RCT pathway 
(Rodriguez-Agudo, Ren et al. 2008).  Finally, StARD4 decreases another 
intracellular transporter, NPC1’s expression.   NPC1 is involved in 
intracellular uptake of cholesterol from endocytosed particles that enter the 
endosomes.  Its mutation leads to a deadly disease, Niemann Pick C disease 
whose pathogenesis is linked to increase lipid droplet formation (Soccio 
and Breslow 2004).  Although the connection is unclear, StARD4, likely in 
combination with another yet uncharacterized protein, plays a role in 





Chapter 3: Epigenetic Regulation Of ApoA-I 
To begin to analyze the transcriptional and epigenetic regulation of 
the ApoA-1 promoter, an in-vitro based experimental system was 
established.  Previous literature has shown that ApoA-I expression is 
limited to the liver and intestine, with the liver being responsible for the 
majority of ApoA-I production (Rader 2006).  Therefore, it made sense to 
investigate liver cells, HepG2 and HuH7, intestinal cells, Caco2 and Ls180 
and a non-expressing cells like BJ and HEK-293T fibroblasts.  It was 
hypothesized that analysis of the differences between an expressing cell 
line and a non-expressing cell line could help elaborate the mechanistic 
steps that allowed for activation of the ApoA-I promoter or conversely 
reveal the inhibitory mechanism that turns the ApoA-I promoter off.   With 
this in mind, the following experiments were undertaken. 
 Expression of ApoA-I in Various Cell Lines 
 It was first necessary to experimentally verify the expression level of 
ApoA-1 in the various cell lines chosen, HepG2, HuH7, HEK-293T, 
Caco2, BJ and LS180.  To do this, ApoA-I primers were designed and 
qPCR run on RNA collected from 3 individual cell lines of each cell type.  
As expected HepG2 (liver) and Caco2 (intestine) both had high levels of 
relative expression, while HEK-293T and BJ (fibroblast) had near baseline 
expression.  Surprisingly, HuH7 (liver) and LS180 (intestine), cells derived 
from tissues thought to express ApoA-I, had near baseline expression.  This 
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was an unexpected and potentially exciting result as it was thought that 
these cell lines might provide a middle ground between the expressing and 
non-expressing cell lines that might require fewer steps compared to non-

















Figure 3.1 - Expression Level of ApoA-I in Various Cell Lines  
qPCR was run on various cell lines, HepG2, HuH7, HEK-293T, Caco2, BJ and 
LS180, to check for the expression level of ApoA-I, High relative expression was 
found in the HepG2 and Caco2 cell line.  Near baseline expression was found in 
the HuH7, HEK-293T, BJ and LS180 cell lines. 
 
Perturbation of ApoA-I with 5-Aza-Deoxycytodine & Trichostatin A 
 To better understand the inhibitory mechanisms of ApoA-I 
expression, HepG2, HuH7, HEK-293T and LS180 cells were treated with 
two transcription “activators”, 5-aza deoxycytidine, a DNA demethylating 
agent and trichostatin A, a HDAC inhibitor, to see if ApoA-I gene 
expression could be activated.  This experiment was conducted with special 
interest in the HuH7 and Ls180 cell lines, as they are both originated from 
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ApoA-I expressing tissues sources, but initially had baseline ApoA-I 
expression.  It was hoped that perhaps a one or two step treatment, could 
stimulate or even restore normal ApoA-I expression.  To reduce the size of 
the experiment, only one true negative non-expressing cell line, HEK-293T 
and one true positive expressing cell line, HepG2, were included.   
As expected, there was minimal change seen in the HepG2 cells 
when treated with 5-aza deoxycytidine (2.5μM) or Trichostatin A (5ng/ml).   
Likewise, 5-aza deoxycytidine or Trichostatin A had little effect in HEK-
293T, which corroborated our initial hypothesis that these cells would have 
multiple levels of gene expression inhibition.  However, interestingly, 
HuH7 when treated with 2.5 μM 5-aza deoxycytidine alone seemed to have 
an approximate 10 fold increase in expression over baseline.  This 
implicated a role for methylation in the regulation of the ApoA-I promoter.  
Trichostatin A did not have a significant effect on the HuH7 cells, 
seemingly ruling out a role for histone acetylation in ApoA-I gene 
expression regulation.  LS180 cell lines did not respond significantly to the 
treatments and their response was only moderate as compared to the HuH7 
cells.  LS180 cells were not used throughout the rest of the experiments.   
All quantities of 5-aza-deoxycytidine and trichostatin A were first 




















Figure 3.2 - Expression Level of ApoA-I After Treatment with 5-Aza-
Deoxycytidine or Trichostatin A (TSA) 
qPCR was run on various cell lines, HepG2, HuH7, HEK-293T, and LS180, to 
check for the expression level of ApoA-I,  Cells were treated with 5-aza-
deoxycytidine, trichostatin A (TSA) or both to check for perturbations in 
expression.  High relative expression was found in the HepG2 as predicted.    
Near baseline expression was found in the HEK-293T and LS180 cell lines.  
Surprisingly, ApoA-I expression was stimulated by 5-aza-deoxycytidine treatment 
in HuH7 cells.  
 
 Bisulfite Sequencing of the ApoA-I Promoter 
  Since ApoA-I promoter methylation was previously implicated in 
tissue specific control of ApoA-I in embryonic cells by Razin et al., it was 
next examined in expressing cells, HepG2 and non expressing cells, HuH7 
and HEK-293T, by bisulfite sequencing (Shemer, Kafri et al. 1991).  
Bisulfite sequencing acts by converting all cytosines to uracils in a stretch 
of DNA unless the cytosine is protected by a CpG methylation mark.  Thus, 
when these stretches are sequenced, any cytosine that appears in the 
sequencing output will be from a protected methylation mark. It is in this 
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manner that bisulfite sequencing can determine the state of methylated in a 
given DNA region.   A depiction of the normal ApoA-I promoter region’s 
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Figure 3.3 - Depiction of ApoA-I Methylation Patterning 
The ApoA-I promoter between ~ -300  400 bp and each individual CpG island 
(represented by a yellow circle).  The critical transcription factor binding region is 
represented with a blue box around it.  Individual locations of CpG islands are 
represented to the right of the figure. 
 
 
 In my experimental design, particular interest was paid to the HuH7 
cells, due to the increase previously found in ApoA-I expression when 
treated with the demethylating agent, 5-aza-deoxycytodine.  The HepG2 
cell line, whose ApoA-I expression is up-regulated, was used as a negative 
control as it was assumed it would show no signs of methylation, while the 
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HEK-293T were used as a positive control, since its ApoA-I expression 
was down-regulated and it was assumed that its ApoA-I promoter region 
would be highly methylated.  However, it was unclear to what extent HuH7 
cells lines would or would not be methylated. 
           As is shown in figure 3.4, HepG2 and HEK-293T cells both 
exhibited expected methylation patterning.  HepG2, whose expression of 
ApoA-I is up-regulated, were unmethylated, while HEK-293T, whose 
expression is down-regulated, were methylated.  However, HuH7 cells 
displayed an unexpected behavior.  It appeared that all CpG islands were 
methylated from the critical transcription factor binding site to the CpG 
islands 300bp’s upstream of the transcriptional start site.  Conversely, the 
CpG islands upstream of the critical transcription factor binding site were 
unmethylated, in contrast to the inactivated HEK-293T cells.  This was 
interpreted as a possible explanation for the intermediate phenotype 
discovered during the administration of the 5-aza-deoxycytidine.  It was 
hypothesized that HuH7’s behavior was one of a transcriptional 
intermediate between non-expressing and expressing cell lines and would 
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Figure 3.4 - Depiction of ApoA-I Methylation Patterning in HepG2, HuH7 
and HEK-293t Cells. 
The ApoA-I promoter between ~ -300  400 bp and each individual CpG island 
(represented by a yellow circle).  The critical transcription factor binding region is 
represented with a light blue box around it.  Individual locations of CpG islands 
are represented to the right of the figure.  Blue circles represent unmethylated 
CpG’s, yellow circles represent, methylated CpG’s and clear circles represent 
CpG’s not covered by the bisulfite sequencing.  Each line represents an individual 
cell line’s DNA, thus each experiment was done in 5 separate cell isolates. 
 
Chromatin Immuno-Precipitation Analysis of the ApoA-I Promoter  
 As both a complementary and alternative approach to analyzing 
the ApoA-I promoter, chromatin immuno-precipitation (ChIP) was 
undertaken to try to localize epigenetic marks that might influence the 
ApoA-I promoter transcription.   ChIP is similar to many traditional types 
of IP, but varies in that one can probe for marks that are transiently bound 
to DNA.  This is done by crosslinking the proteins to the DNA with 
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formaldehyde, fragmenting the DNA into 200-800bp fragments via 
sonication, probing the DNA with the antibody(Ab) of choice, 
immunoprecipitating DNA and utilizing PCR to demonstrate the amount of 
protein associated with your DNA region of interest, in our case, ApoA-I.   
Epigenetic marks tested included, H3K27 tri-methyl, a commonly 
associated inhibitory mark, H3K9 di-methyl, a common inhibitory mark 
associated with DNA methylation inhibition, H3 acetyl and H3K9 acetyl, 
two common activation marks, not including the most common H3K4 tri-
methyl activation mark and MBD2, the most common member of a protein 
family that directly binds methylation marks associated with DNA CpG 
islands (Jenuwein and Allis 2001).  These marks were hypothesized to offer 
additional insights to the previously discovered methylation patterning 
described by bisulfite sequencing.     
 Initial discoveries with ChIP were inconclusive.  However, it did 
seem to verify that inhibitory markers such as H3K9 di-methyl and H3K27 
tri-methyl were present in HEK-293T cells and in HuH7 cells and not 
present in the HepG2 cells.   Unfortunately, activation marks were not 
subsequently found in the HepG2 cells. 
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Figure 3.5 - ChiP Analysis of the ApoA-1 Region  
The ApoA-I promoter was probed with the antibodies listed above.  The Input is 
the total DNA isolated before it is exposed to any AB (positive control) and the 
IgG is an AB that should not immunoprecipitate anything (negative control).   
HepG2 cells unfortunately show now activation marks to coincide with the 
previous methylation pattern.  HuH7 and HEK-293T both have inhibitory marks 
that indicate a mechanism for their phenotype.  Interestingly and coinciding with 
the methylation work, HuH7 cells have a mark for H3K9 di-methyl, a marker for 
methylation inhibition.   
 
qPCR of Various Liver Proteins and Methyl Binding Factors 
 Next, relative expression levels of two other common liver enriched 
proteins, ApoE and Albumin were measured in all three cell lines.  This 
was done to check that the expression patterning found, specifically in 
HuH7, was due to actual changes in ApoA-I regulation and not an 
idiosyncrasy of HuH7 cells themselves, in comparison to HepG2 
expression profiles.  Additionally, I checked the expression of genes in the 
methyl binding family, MBD1, MBD2, MeCP2-1 and Kaiso to see if one in 
particular had an elevated expression pattern.   
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 Both Albumin and ApoE had similar expression between HepG2 and 
HuH7 liver cells, with no expression in the HEK-293T cells.  None of the 
methyl binding patterns, based on mRNA expression, showed striking 















































Figure 3.6 - qPCR of HepG2, HuH7 and HEK-293T Cell Lines With 
Common Liver and Methyl Binding Protein Primers 
qPCR was run on three individual samples from HepG2, HuH7 and HEK-293T 
cells to check for expression patterning of the above listed genes. 
 
Expression of ApoA-I in a New Set of HuH7 Cell Lines 
 To more precisely quantify ApoA-I expression absolute expression 
levels were determined in each cell line.   At this time, it was necessary to 
thaw a new vial of cells, as the cells used for the last experiments were 
utilized and no cells remained cultivated in cell culture.  Much to our 
surprise, the new vials of cells had a different patterning of ApoA-I 
expression as compared to our original results.  Specifically, the new 
thawed HuH7 cells had higher levels of ApoA-I expression than initially 
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reported.  This raised concerns and required the repetition of initial 
experiments. 






















Figure 3.7 - Absolute qPCR of HepG2, HuH7 and HEK-293T Cell Lines With 
the ApoA-I Primers 
qPCR was performed on three individual samples from all cell lines.  Absolute levels 
of ApoA-I was highest in the HepG2 cells, with a little bit lower levels in the HuH7-
new cells and baseline levels in the HuH7-old cells and HEK-293T cells. 
 
5-Aza-Deoxycytidine Treatment of the New Set of HuH7 Cells 
 With the expression pattern of ApoA-I in HuH7 cells called into 
question, it was important to test the effect of 5-aza-deoxycytidine on the 
new HuH7 cells.  This experiment was also repeated in HepG2 and HEK-
293T cells as positive and negative controls, respectively.  The cells were 
exposed to the two most common amounts of 5-aza-deoxycytidine, 2mM 
and 5mM.  All numbers reflected in this experiment are absolute expression 
levels.  Unfortunately, once the experiment was completed, it was revealed 
that the 5-aza-deoxycytidine treatment had no effect on the freshly thawed 
vial of HuH7 cells (Figure 3.8).   
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Figure 3.8 - Absolute qPCR of HepG2, New HuH7 and HEK-293T Cell Lines 
treated with 5-AZA-Deoxycytdine and probed with ApoA-I Primers  
qPCR was run on three individual samples from all cell lines.  Absolute levels of 
ApoA-I was highest in HepG2 and did not seem to vary in any of the lanes treated 
with 5-aza-deoxycytidine.  This is contradictory to what we saw earlier with the old 
HuH7 cells. 
 
Re-Sequencing of the Original Set of HuH7 Cells 
 Based on the previous two experiments, I decided to sequence the 
promoter regions of the cell lines and extend the bisulfite sequence to 
regions farther upstream of the promoter.  The sequencing results revealed 
that the original HuH7 cell line, but not the freshly thawed vial, had a DNA 
deletion in the -500 to -550 region upstream of the ApoA-1.  This area 
might be essential for binding of various elements of the transcriptional 
machinery and might explain the increased expression initially reported in 
HuH7 cells.  It might also explain why that region, which was reanalyzed 
for CpG islands, remained unmethylated.   
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Old Huh7 (human hepatoma cells)
Hek-293T  (human embryonic kidney fibroblasts)
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Figure 3.9 - Sequencing and Extended Bisulfite Coverage of the ApoA-I promoter  
Analysis of the HepG2, old HuH7 and HEK-293T cells was furthered by sequencing the 
promoter and extending the bisulfite analysis upstream of what was previously done.  
Sequencing revealed a deletion (represented in red) in the ApoA-I promoter of original 
HuH7 cells that could explains its increased expression patterning as compared to the 
same cell line thawed from a different vial. 
 
 The promoter deletion discovered in the original HuH7 cells 
invalidated much of my initial efforts to try and describe an intermediary 
step between the HepG2 activated state and the HEK-293T inhibitory state.  
It is possible that the discrepancy found between the two cells lines was due 
to a mutation that occurred due to the passaging of the original cells too 
many times.  However, this problem still remains unsolved.  Although, it 
would still be interesting to analyze the machinery controlling ApoA-I 
expression, by ChIP and other techniques, much of the work done initially 
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for this thesis was no longer insightful.  At this point, further progress on 
the StARD4 project was being made and it was collectively decided to 
proceed in that direction. 
Summary  
 Due to the difficulties encountered while analyzing the ApoA-I 
promoter and the timing of the project with the StARD4 mouse, much of 
the work on the ApoA-I promoter and its transcriptional machinery was 
abandoned.  However, this remains a viable and open area of research.  
There remains critical issues to uncover about the mechanisms controlling 
the ApoA-I transcriptional machinery.  The bisulfite sequencing experiment 
showed here the extent of the unmethylation of an activated ApoA-I gene.  
ChIP experiments gave hints to the role of H3K27 and H3K9 in inhibition 
of the ApoA-I gene.  Further studies, described in greater detail in the final 
chapter of this thesis, will elucidate mechanism that will provide crucial 
insight into the machinery that controls ApoA-I and hopefully lead to a 
therapeutic remedy to help patients continue to manage their cholesterol in 







Chapter 4: Materials and Methods 
Animals and Diets: 
All animal protocols were approved by The Rockefeller University 
Animal Care and Use Committee. All mice were bred and housed at the 
Rockefeller University Laboratory Animal Research Center in a single 
humidity and temperature controlled room with a 12h dark-light cycle. 
Fertility and Number Offspring Born/Pregnancy:  To assess 
fertility and number offspring born/pregnancy, littermate knockout males 
(> 6 weeks old) were placed in cages with mature wild-type females for 1 
month or longer.  The same was done for female knockouts.  All offspring 
was subsequently recorded. 
Mice: Wild-type C57BL/6 male mice were obtained from the 
Jackson Laboratory (stock no. 00664).  ACTFLPe transgenic mice on the 
C57BL/6 background were obtained from the Jackson Laboratory (B6.Cg-
Tg (ACTFLPe) 9205Dym/J, stock no. 005703, henceforth called Flp). 
These mice express flippase in all mouse tissues. CMV-Cre transgenic on 
the C57BL/6 background were obtained from the European Mutant Mouse 
Archive (EMMA) (B6.129P2-Tg(CMV-cre)1Cgn/CgnIbcm, stock no. 
01149, henceforth called CMVCre).  These mice express Cre-recombinase 
in all mouse tissues.  Alb-Cre transgenic mice on the C57BL/6 background 
were obtained from the Jackson Laboratory (B6.Cg-Tg(Alb-cre)21Mgn/J, 
stock no. 003574, henceforth called Alb-Cre). These mice express Cre-
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recombinase in hepatocytes. LysM-Cre transgenic mice on the C57BL/6 
background were obtained from Ira Tabas. These mice express Cre-
recombinase mainly in the reticuloendothelial system, particularly 
macrophages. LDLR–/– mice on the C57BL/6 background were obtained 
from the Jackson Laboratory (B6.129S7-Ldlrtm1Her/J, stock no. 02207, 
henceforth called LDLR–/–). Albino mice on the C57BL/6 background 
were obtained from the Jackson Laboratory (B6(Cg)-Tyrc-2J/J, stock no. 
000058, henceforth called albino).  
To assess fertility, one littermate female or male (>6 weeks old) was 
placed in a cage with a littermate of the opposite sex for 1 month or more. 
The number of female mice achieving pregnancy and the number of 
offspring from each pregnancy was recorded. 
Dietary Studies:  Characterization of StARD4 knockout mice was 
done on animals fed a chow diet ad libitum (PicoLab Rodent Diet 20).  
Unless otherwise indicated, mice were weaned at 4 weeks of age, fed the 
chow diet for 8 weeks, and then experimented on and sacrificed at 12 
weeks of age 
A comparison of the effects of different diets on StARD4 knockout 
mice was done by placing 6 week old mice on a modified AIN76a semi-
synthetic diet (12% kcal fat and 0.00% cholesterol) (Research Diets 
D10001) for 1 week, whereupon the mice were split into 3 groups: a control 
group continued the AIN76a diet, a lovastatin group fed the AIN76a diet 
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plus 0.2% lovastatin (Research Diets D09020602), and a cholesterol fed 
group fed the AIN76a diet plus 0.5% cholesterol (Research Diets 
D09020601). These diets were fed for 1 week and the mice were studied 
and sacrificed at 8 weeks of age. 
Another diet study was done by switching 8 week old chow fed 
StARD4 knockout mice to a high fat diet (60% kcal fat) (Research Diets 
D09020601-02) for 12 weeks and sacrificing them at 20 weeks of age. 
Atherosclerosis studies were done on StARD4 knockout mice bred 
on to the LDLR-/- background.  These mice were fed the modified AIN76a 
diet containing 0.02% cholesterol (Research Diets D00110804) from 
weaning at 4 weeks to sacrifice at 20 weeks of age.  
Sacrifice of Animals 
The general mouse sacrifice protocol was as follows.  On the 
morning of sacrifice, food was removed from the cage early in the light 
cycle (~9am) and mice were fasted with free access to water for the next 6 
hours (~3pm).  Blood glucose levels were measured from tail blood using a 
glucometer (Bayer).  The mice were then sedated with ketamine/xylazine, 
weighed, blood was removed by puncturing the right and then left heart 
ventricles with an EDTA coated needle, the gallbladder bile was aspirated 
into individual tubes and finally the mice were perfused with heparinized 
PBS by sticking a needle into the left ventricle and allowing the PBS to 
flow via the circulation.  Tissues were then harvested, weighed and frozen 
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in liquid nitrogen and stored at -80C.  For atherosclerotic studies, mice 
were perfused with heparinized PBS and the heart was removed by cutting 
halfway between the aortic root and the brachiocephalic artery. The tissue 
was frozen in Tissue-Tek OCT compound. The brachiocephalic artery was 
cut at the point where it branches from the aorta and 1mm distal to its 
bifurcation into the subclavian and carotid arteries.  
Creation of Knockout Mice 
Conditional StARD4 knockout mice were made using the 
recombineering method originated by Copeland 
(http://recombineering.ncifcrf.gov/default.asp). Freshly prepared BAC 
DNA (BacPac Resources http://bacpac.chori.org, clone # RP23-46E14) was 
used.  All primer sequences used for constructing the StARD4 conditional 
knockout vectors are listed in Table 5.1. ROCHE Expand High-Fidelity 
Taq kit was used for PCR amplification using the manufacturer’s 
instructions.  PCR product purification was done with QIAGEN spin 
columns, followed by digestion with the appropriate restriction enzyme 
(NEB), and purification with QIAGEN spin columns.  
The retrieval vector was generated by mixing 3 μL of PCR product 1 
(A-B, NotI/HindIII), 3 μL of PCR product 2 (Y-Z, HindIII, BamHI), 2 μL 
of MC1TK (PL253, NotI/BamHI), 1 μL of 10x ligation buffer, and 1 μL of 
T4 DNA ligase. The loxP-Neo-loxP targeting vector  was generated by 
mixing 3 μL of PCR product 1 (C-D, NotI/EcoRI), 3 μL of PCR product 2 
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(E-F, BamHI/SalI), 2 μL of floxed Neo cassette (PL452, EcoRI/BamHI), 1 
μL of pSK+ (NotI/SalI), 1.2 μL of 10x ligation buffer, and 1 μL of T4 DNA 
ligase. The frt-Neo-frt-loxP targeting vector was generated by mixing 3 μL 
of PCR product 1 (G-H, NotI/EcoRI), 3 μL of PCR product 2 (I-J, 
BamHI/SalI), 2 μL of floxed Neo cassette (PL451, EcoRI/BamHI), 1 μL of 
pSK+ (NotI/SalI), 1.2 μL of 10x ligation buffer, and 1 μL of T4 DNA 
ligase. The ligation mixtures were incubated at 16°C for 2 h, and 0.5 μL 
was transformed by electroporation into electro-competent DH10B cells 
(Invitrogen).  
Briefly, the recombineering steps taken were as follows. 1 μL of 
fresh BAC DNA (100 ng) was electroporated into EL350 cells.  
Concomitantly, the EL350 cells were incubated with the modified retrieval 
vector PL253 described above.  What is unique to the recombineering 
protocol, is that PL253 after digestion and linearization with HindIII has 
two ends homologous (PCR product AB and YZ) to the StARD4 genomic 
region of interest.  Therefore, subsequent electroporation and selection with 
ampicillin retrieves EL350 cells containing plasmid DNA with the StARD4 
genomic DNA. Second, the plasmid DNA is extracted and recombined with 
the modified minitargeting vector (PL452), which adds the LoxP cassette.  
This plasmid is then electroporation again into El350 cells and selected by 
ampicillin and kanamycin. Third, Cre expression, inducible in El350 cells 
when put into media containing arabinose, was activated and the cassette 
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from PL452 was removed leaving behind a singular LoxP site.  Fourth, 
plasmid DNA was again extracted from the EL350 cells and another two 
FRT sites and one Loxp site were added from the modified minitargeting 
vector (PL451), in the same manner described above.  The plasmid DNA 
was once again recombined in EL350 cells, selected by ampicillin and 
kanamycin and correctly recombined plasmid DNA recovered.   This 
construct would ultimately be recombined in a flippase mouse to create a 
StARD4 gene with two LoxP sites flanking exon 3 of StARD4. 
All cloning junctions and loxP and Frt site orientations were 
sequence verified, using forward and reverse sequencing primers. For gene 
targeting, 20 μg of NotI-linearized cko-targeting vector DNA was 
electroporated into ES cells by The Rockefeller University Gene Targeting 
Facility. To screen for ES clones with homologous recombination, southern 
blotting with probes upstream and downstream of the targeting construct 
were designed. For StARD4, one positive ES clone was obtained, injected 
into blastocysts and implanted into carrier mouse wombs, which resulted in 








 Table 4.1 - Primers for Recombineering 
Primers for Creating StARD4cKO 
Primer 
  ID  Primer Description   Sequence 
  A  NotI-StARD4 promoter for  ATAATGCGGCCGCTTGATCTGTACCCGAGAGGT 
  B  HindIII-StARD4 promoter rev GCAGAAGCTTTGTAGTCAGGAAAGGCCAGT 
  C  NotI-StARD4 intron2-3 for          ATAAGCGGCCGCGTGTGGAATGGATGTACAAT 
  D  EcoRI-StARD4 intron2-3 rev  GCGGGAATTCCGTGTCTGATATCAGTGCAA 
  E  BamHI-StARD4 intron 2-3 for  ATAAGGATCCAGAGCGTGTGAGTGGACAGT 
  F  SalI-StARD4 intron 2-3 rev  GTCAGTCGACTTTCAGTAGCTCAGAGATCC 
  G  NotI-StARD4 intron3-4 for          TTATGCGGCCGCCAGAGATGAATACTCAGCAT 
  H  EcoRV-StARD4 intron3-4 rev  CCACGATATCCAATCTTCCTGTCCAGGTCA 
   I   BamHI-StARD4 intron 3-4 for  TTACGGATCCGTCAGCAGTCTAGGAATGAG 
  J  SalI-StARD4 intron 3-4 rev  ATCTGTCGACAACTAGGCCAGAGGGCAAAT 
  Y  HindIII-StARD4 intron 4-5 for  GCCTAAGCTTCACACCCACACATGAGTGAA 
  Z  BamHI StARD4 intron 4-5 rev  ACATGGATCCCTCAACATTCAGAAGGAGGG 
To introduce ~8.5kb BAC into PL253/Retrieval Vector 
AB ~280bp 
YZ ~320bp 
To introduce loxPNeoLoxP (PL452) into StARD5 
CD ~180bp 
EF ~360bp 




Animal tail tips were digested overnight with proteinase K and then 
ethanol precipitated for DNA isolation.  Primers and sequences are listed in 
Table 5.2. 
Conditions for genotyping Flp: 5 min 940C; 35 cycles of 30 sec 
940C, 1 min 580C, 1 min 720C; 5 min 720C. 
Conditions for genotyping CMV-Cre: 3 min 940C; 12 cycles of 20 
sec 940C, 30 sec 640C, 35 sec 720C; 25 cycles of 20 sec 940C, 30 sec 580C, 
35 sec 720C; 5 min 720C. 
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Conditions for genotyping Alb-Cre: 5min 940C; 35 cycles of 30 sec 
940C, 1 min 510C, 1 min 720C; 5 min 720C.  
Conditions for genotyping LDLR-/-: 5 min 940C; 10 cycles of 20 sec 
950C, 30 sec 640C, 1 min 720C; 30 cycles of 20 sec 950C, 30 sec 580C, 1 
min 720C; 5 min 720C.  
Conditions for genotyping StARD4cko AH: 5min 940C; 35 cycles of 
30 sec 940C, 45 sec 540C, 1:00 min 720C; 5 min 720C.  
Conditions for genotyping StARD4cko CH: 5min 940C; 35 cycles of 
30 sec 940C, 30 sec 620C, 45 sec min 720C; 5 min 720C  
For StARD4cko southern blotting, genomic DNA was digested with 
either EcoRV (5’ probe) or EcoR1 (3’ probe) and probed with genomic 
DNA upstream or downstream of the targeted genomic sequence. All 













Table 4.2 - Sequences of Primers Used for Genotyping  
 
Primers Used for PCR Genotyping 
  Genotype   Name of Primer  Sequence 
  ACTFLPe   oIMR0042   CTAGGCCACAGAATTGAAAGATCT 
oIMR0043  GTAGGTGGAAATTCTAGCATCATCC 
oIMR1348   CACTGATATTGTAAGTAGTTT 
oIMR1349   CTAGTGCGAAGTAGTGATCAG 
  LysM-Cre   Cre8    CCCAGAAATGCCAGATTACG 
Mlys1    CTTGGGCTGCCAGAATTTCTC 
Mlys2    TTACAGTCGGCCAGGCTGAC 
  CMV-Cre   oIMR0042   CTAGGCCACAGAATTGAAAGATCT 
oIMR0043   GTAGGTGGAAATTCTAGCATCATCC 
oIMR0567   ACCAGCCAGCTATCAACTCG 
oIMR0568   TTACATTGGTCCAGCCACC 
  Alb-Cre   oIMR0042   CTAGGCCACAGAATTGAAAGATCT 
oIMR0043  GTAGGTGGAAATTCTAGCATCATCC 
oIMR1084   GCGGTCTGGCAGTAAAAACTATC 
oIMR1085   GTGAAACAGCATTGCTGTCACTT  
  LDLR    IMR59    CGCAGTGCTCCTCATCTGACTTGT 
IMR46    ACCCCAAGACGTGCTCCCAGGATGA 
IMR14    AGGTGAGATGACAGGAGATC 
  StARD4cko deletion  StARD4 A (ex2for) CTGGAAGGACTGTCTGATGT 
StARD4 C (ex3for) CTGCTGACCCACTTTGTAT 
StARD4 H (int3-4rev)  CTATTCTTCTCTGAGTCCCT 
         floxed  StARD4 C (ex3for) CTGCTGACCCACTTTGTAT 
StARD4H (int3-4rev)  CTATTCTTCTCTGAGTCCCT              
                      Neo  StARD4 C (ex3for) CTGCTGACCCACTTTGTAT 
StARD4neorev   GTAGAATTTCGACGACCTGC 
  
Primers used For Southern Blotting 
  Genotype   Name of Primer  Sequence 
  StARD4cko Upstream  5’ Upstream Forward TCATCGATTGGGTCTGAGCA 
  5’ Upstream Reverse CCAGCATGTCAAGATATACCC 
       Downstream  5’ Upstream Forward CTGAGAGTAGAGTGGTGTGT 
5’ Upstream Reverse ATAAGCACTGTGCACATGCC 
 
 
Mouse Plasma, Liver, and Gallbladder Analysis 
At sacrifice, blood was immediately centrifuged and plasma 
separated and kept at 4°C. Lipoproteins were isolated by sequential 
ultracentrifugation from 60 μl of plasma at d <1.006 g/ml [very low-density 
lipoprotein (VLDL)], 1.006 ≤d ≥1.063 g/ml (intermediate-density 
lipoprotein and LDL), and d >1.063 g/ml (high-density lipoprotein). Total 
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plasma and lipoprotein cholesterol were measured enzymatically 
(Roche/Hitachi).  In each fraction you measure total cholesterol, with the 
cholesterol esterase present and free cholesterol, without the cholesterol 
esterase present and the difference is cholesterol ester.  Total plasma 
triglycerides were measured enzymatically (Roche). 
Gallbladder bile was isolated and analyzed for cholesterol, 
phospholipids, and bile acids enzymatically (Roche, Wako).  
Total liver lipids were extracted from liver by the Folch method. 
Briefly, snap-frozen liver tissues (~100 mg) were homogenized with a 
dounce homogenizer and extracted twice with chloroform/methanol (v/v = 
2:1) solution. The organic layer was dried under nitrogen gas and 
resolubilized in chloroform containing 2% Triton X-100. This extract was 
dried again and resuspended in water and then assayed for total cholesterol 
and triglycerides enzymatically with commercial kits as described above.  
Quantification of Atherosclerosis 
To quantify cross-sectional lesion area in the aortic root, heparinized 
flushed hearts were embedded in OCT. In cutting the aortic root, 
orientation is important and the heart was placed in such a way that sections 
were cut with the 3 aortic valves in the same plane.  Cutting was begun 
immediately once the valves are viewed and sections were saved on glass 
slides every 12μm in thickness. Sections were stained with oil red O and 
lesion area quantified by the level of staining of the internal elastic lamina 
 130
in every fourth section.  For any mouse in which atherosclerosis was 
assessed, aortic root lesion area was the average of 5 of these sections.  To 
quantify cross-sectional lesion area in the brachiocephalic artery, the Y-
shaped piece of brachiocephalic artery was sectioned distally to proximally 
at 10μm thickness, beginning from the branch point for the subclavian and 
carotid arteries. Atherosclerotic lesions luminal to the internal elastic 
lamina were quantified by oil red O-stained sections at 200, 400, and 600 
mm from the branching point of the brachiocephalic into the carotid and 
subclavian arteries. 
Intraperitoneal Glucose Tolerance Test 
Intraperitoneal Glucose Tolerance Tests (IPGTT) were performed on 
mice 3-4 days prior to sacrifice.  On the morning of the test, food was 
removed from the cage early in the light cycle (~9am), and mice were 
fasted with free access to water for the next 6 hours (~3pm).  Glucose was 
then injected intraperitoneally in physiologic saline (2g/kg of body weight) 
and blood drawn from the tail vein at 0, 15, 30, 60 and 120min.  Glucose 
levels were measured in these whole blood samples with a handheld blood 
glucometer (Bayer).  
Body Composition Analysis 
 Body composition and bone mineral content and density of StARD4 
knockout mice were assessed by dual energy X-ray absorptiometry (Dexa) 
scanning.  Mice were anesthetized with isofluorane and put on the scanning 
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plate of the Piximus 2 (Lunar) Dexa scan.  Data was collected, and 
following the procedure the mice were allowed to recover unaided.  
Sample Preparation for Gene Expression Analysis 
Total RNA was isolated from cultured cells or tissues using TRIzol 
reagent (Invitrogen) and then subjected to RNeasy Cleanup (Qiagen) prior 
to analysis of gene expression by microarray and RT-PCR.  In both cases 
the manufacturer’s instructions were followed. 
Quantitative RT-PCR 
For RT-PCR analysis, total RNA was treated with Dnase I 
(Ambion), and 1-5μg was reverse transcribed using Superscript III 
(Invitrogen) with random hexamer primers. A 7900HT Sequence Detection 
System (Applied Biosystems) was used with the thermal cycling profile, 
950C for 10 min; 40 cycles of 950C 30 sec, 550C 30 sec, 720C 1 min; 950C 
15 sec, 600C 20 sec, 950C 15 sec (dissociation curve for SYBR Green 
reactions) unless otherwise specified. The threshold was set in the linear 
range of normalized fluorescence, and a threshold cycle (Ct) was measured 
in each well. Each sample was amplified in duplicate for the genes of 
interest and the housekeeping gene, GAPDH.  cDNA values for genes of 
interest were then normalized to the corresponding value for the 
housekeeping gene GAPDH and expressed as a ratio, allowing for 
variability in the initial quantities of mRNA used in the amplification 
reactions.  All primers are listed in Table 5.3. 
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Table 4.3 - Sequences of Primers Used for qPCR  
 
Primers Used for qPCR  
  Gene Name (anneal) Name of Primer  Sequence 
  NPC1                NPC1-For  CTTAGTGCAGGAACTCTGTCCAGG 
             NPC1-Rev  TCCACATCACGGCAGGCATTGTAC 
  NPC2                NPC2-For  CACTCAGTCCCAGAACAGCA 
             NPC2-Rev  AGTTTCCATTCCACCACCAG 
  MLN64              MLN64-For  CACCTCTGGAGAAGCGTAGG 
             MLN64-Rev  AGAACGAGCTCTGGAAGCTG 
 Caveolin 1     (56oC)      Cav1-For              GCGGTTGTACCGTGCATCAAGAG 
             Cav1-Rev  CGGATGTTGCTGAATATCTTGCC 
 Caveolin 2     (60oC)      Cav2-For              CCTCACCAGCTCAACTCTCATCTC 
             Cav2-Rev  CAGATGTGCAGACAGCTGAGG 
 Caveolin 3     (60oC)      Cav3-For              GGAGATAGACTTGGTGAACAGAGA 
             Cav3-Rev  CAGGGCCAGTGGAACACC 
 StAR              (48oC)      StAR-For              GCAGCAGGCAACCTGGTG 
             StAR-Rev  TGATTGTCTTCGGCAGCC 
 StARD4                         StARD4-For              GTGATGCGTTACACCACTGC 
             StARD4-Rev  CCACGGACAAACTCTGGTCT 
 StARD5                         StARD5-For              GGAAGGCAATGGAGTTTCAA 
             StARD5-Rev  ATCCCACACCTCTTCTGGTG 
 GAPDH                         GAPDH-For              AACTTTGGCATTGTGGAAGG 
             GAPDH-Rev  GGATGCAGGGATGATGTTCT 
              LDLR         (60oC)          LDLR-For                      TGACTCAGACGAACAAGGCTG 
                                                    LDLR-Rev                      ATCTAGGCAATCTCGGTCTCC 
              HMGCR     (60oC)         HMGCR-For                  AGCTTGCCCGAATTGTATGTG 
                                                    HMGCR-Rev                 TCTGTTGTGAACCATGTGACTTC 
              ApoA-I                           ApoA-I For                     GCCTTGGGAAAACAGCTAAACC 




       All protocols were conducted as described in the Illumina GeneChip 
Expression Analysis technical manual with the help of Wenxiang Zhang 
and Connie Zhao at the Rockefeller Genomics Facility. The quality of total 
RNA prepared from 10 to 20mg of wet tissue was assessed using the 
Agilent 2100 Bioanalyzer, RNA 6000 Nano kit (Agilent Technologies Inc., 
Palo Alto, CA) and manually by gel electrophoresis.  Quality RNA was 
determined by the density of the 18s and 28S fractions and by lack of DNA 
contamination.  ~500 ng of high quality total RNA was then biotinylated 
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using the Ambion Illumina TotalPrep RNA Amplification Kit (Cat# 
AMIL1791, Applied Biosystems, Foster City, CA). 
            Briefly, 500 ng of high quality total RNA was used as the template 
for first strand cDNA synthesis by ArrayScript reverse transcriptase with an 
oligo primer bearing a T7 promoter (Garofalo, Orena et al.). The single-
stranded cDNA was then converted into a double-stranded DNA (dsDNA) 
by DNA polymerase I in the presence of /E. coli/ RNase H and DNA ligase. 
After column purification, the dsDNA served as a template for in vitro 
transcription in a reaction containing biotin-labeled UTP, unlabeled NTPs 
and T7 RNA Polymerase. The amplified, biotin-labeled antisense RNA 
(Yancey, de la Llera-Moya et al.) was column purified and checked for 
quality with the Agilent 2100 Bioanalyzer and the RNA 6000 Nano kit. 750 
ng of RNA in 5 μl of Tris-EDTA was mixed with 10 ml of hybridization 
reagents and heated at 65°C for 10 minutes. After cooling to room 
temperature, the RNA in hybridization solution was applied to Illumina 
MouseRef-8 v1.1 chip. The chip was incubated for 18 hours at 58°C. After 
washing and staining with streptavidin-Cy3, the chip was scanned using 
Illumina BeadArray Reader. The standard DirectHyb Gene Expression 
protocol was used with the following settings: Factor=1, PMT=587, 
Filter=100%. The raw data was extracted using Illumina BeadStudio 
software without normalization. 
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Initial Data Analysis — Genespring GX10 software was used to 
quantify expression levels of all genes; default values provided by Illumina 
were applied to all analysis parameters. Border pixels were removed, and 
the average intensity of pixels within the 75th percentile of expression was 
computed for each probe. The average of the lowest 2% of probe intensities 
occurring in each of 16 microarray sectors was set as background and 
subtracted from all features in that sector. Probe pairs were scored as 
positive or negative for detection of the targeted sequence by comparing 
signals from the perfect match and mismatch probe features. The number of 
probe pairs meeting the default discrimination threshold (0.015) was used 
to assign a call of absent, present, or marginal for each assayed gene, and a 
p value was calculated to reflect confidence in the detection call. A 
weighted mean of probe fluorescence (corrected for nonspecific signal by 
subtracting the mismatch probe value) was calculated using the one-step 
Tukey’s bi-weight estimate. This signal value, a relative measure of the 
expression level, was computed for each assayed gene. Global scaling was 
applied to allow comparison of gene signals across multiple microarrays; 
after exclusion of the highest and lowest 2%, the average total chip signal 
was calculated and used to determine what scaling factor was required to 
adjust the chip average to an arbitrary target of 150. All signal values from 




Proteins were isolated from cells or mouse tissues by 
homogenization in RIPA buffer (50 mM Tris, pH 7.4/150 mM NaCl/1 mM 
EDTA/0.1% SDS/1% Triton X-100/1% deoxycholate) containing complete 
mini protease inhibitor cocktail (Roche). Crude extracts were homogenized 
and then centrifuged at 16,000 x g for 10 minutes at 4oC to pellet cellular 
debris and nuclei. Total protein concentration was measured by the BCA 
assay (Pierce), and 10–50 μg of protein was electrophoresed on a 4-12% 
Bis Tris gel and then blotted via western onto a nitrocellulose membrane.  
Protein detection with the following antibody dilutions were carried out: 
anti-StARD4, 1:200 (Santa Cruz: sc-66663) and anti-beta actin (Cell 
Signaling), 1:10,000. To detect the antibody-protein complexes, the 
SuperSignal West Pico or Femto Kits (Pierce) were used according to the 
manufacturer’s instructions. Band intensities were measured with IMAGE 
Pro Plus. 
Data and Statistical Analysis 
All data are expressed as mean ± std. Statistical analysis was 
performed using the student t-test. Because normality could not be assessed 
for our some of the small sample sizes and non-normal distributions have 
been reported in previous larger atherosclerosis studies in mice, the non-
parametric Mann-Whitney test was used to test significance. Significance is 
indicated by an asterisk in the figures/tables. 
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Isolation of Primary Hepatocytes 
 Primary hepatocytes were isolated as follows:  A Rainen Instrument 
rabbit peristaltic pump was primed by running approximately 100ml of 
70% ethanol through the tubing as a disinfectant prior to the procedure.  
After disinfection, the pump was rinsed with 50ml of Hanks’ Balanced Salt 
Solution (HBSS) without Ca2+.   Next, all of the solutions were warmed in a 
40oC water bath and the pump’s flow rate was adjusted to 5ml/min.  While 
this is taking place, the collagenase solution is prepared (75mg of 
collegenase (Worthington – collagenase type 1) in 100ml of HBSS with 
Ca2+ for each mouse. Finally, a petri dish ready to receive each liver 
containing 10ml of Dulbecco’s Modified Eagle Medium is placed on ice. 
 Once the preparation is completed, the mouse is anesthetized, 
exsanguinated, and perfused with heparinized saline, the abdomen is 
opened surgically and a catheter inserted into the inferior vena cava (IVC). 
In the EVC, the catheter is advanced until it reaches the liver and blood 
flows out easily.  The catheter is then connected to the pump primed with 
HBSS without Ca2+, which is turned on and run for 5 minutes.  To reduce 
leakage, the chest cavity is opened and the suprahepatic inferior vena cava 
is clamped.  Then to allow proper perfusion the portal vein is cut.  After 
five minutes have passed, solutions in the pump are changed and the liver is 
then perfused with the collagenase solution for 15 minutes.  At this point 
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the liver, spongy and soft, is removed and placed into the Petri dish that had 
been set on ice.  This process is then repeated for the rest of the mice  
After all the mouse livers have been processed, transfer them in their 
petri dishes to the cell culture hood.  In culture, the livers were minced with 
a razor blade or scalpel until they are sufficiently broken apart for cells to 
be isolated.  Next, the livers are filtered through a cell strainer (40μm nylon 
mesh) into a 50ml Falcon tube.   Upon completion, add DMEM to the 
filtrate to increase the total volume to 50 ml and then pellet the cells by 
centrifuging for 5 minutes at 4oC (20rcf, 0 brake, 0 acceleration).  To rinse 
the cells, aspirate off the DMEM media, add 30ml fresh DMEM, gently 
resuspend the cells, and the repellate them by centrifugation.  Repeat this 
washing procedure 2 more times, but use a higher spin velocity (50-100 rcf 
depending on machine) to repellet the cells.  Finally, once the cells are 
sufficiently clean, suspend the cells in DMEM and count the density with a 
hemicytometer.  Finally, seed between 500,000 – 2,000,000 cells per well 
of a 6 well culture dish and culture at 37°C in 95%air/5%CO2.  The next 
morning cells were checked to see how well they stuck to the culture dish 
and experimentation was started 24-48 hours after cells settled. 
Filipin Staining 
It is possible to stain for the localization of free cholesterol, both in 
the plasma membrane and intracellular compartments, within a cultured cell 
in-vitro with a filipin stain.  Initially, cells are grown by seeding 1 x 106 
 138
cells on a cover slip resting inside a well of a 6 well plate.  Once the cells 
reach 80% confluence they are removed from cell culture, the media 
removed and filipin staining was begun; all following steps are done at 
room temperature.  For each step, use enough media to cover the cover slip 
adequately as to keep the cells hydrated.  First, the cells were washed three 
times in Medium 1 (150mM Nacl, 5mM KCL, 1mM CaCL2, 20mM Hepes 
pH 7.4, 2g/l glucose, H20).  Immediately after the washings, fix the cells for 
20 minutes in 4% paraformaldehyde.  Next, wash the cells two times in 
PBS, aspirate off the excess solution and incubate for 2 hours with filipin 
stain, 1μl per 1ml Medium 1 (Stock Solution- 50mg/ml in DMSO, Sigma – 
F9765; Working Solution - 50μ/ml filipin in Medium 1).   A Sytox Green 
counterstain, 2μl per ml Medium 1, is applied to visualize the nuclei for the 
last 15 minutes of the 2 hour incubation (Stock Solution- 5mM , Invitrogen 
– S7020; Working Solution – 5μM in Medium 1).   At the two hour mark, 
wash the cells an additional three times with Medium 1, mount the cover 
slips onto slides with VectaShield Mounting Solution (Vector Labs – 
H1000) and visualize filipin by fluorescence microscopy with excitation 
between 335-385 nm and emission around 420nm.  Sytox green is 
visualized at 504/523 nm excitation/emission wavelengths.   Slides can be 
kept in the fridge for many months without degradation of signal. 
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Generation of Bone Marrow Macrophages (to differentiate them into 
SRA Expressing Macrophages)  
Bone Marrow Macrophages were generated as follows.  To start, 
sacrifice a mouse, open up its leg cavity, clear the muscle from femur and 
tibia and cut of small portions from each side of the femur or tibia until the 
marrow, which should be red on the inside of the bone, is visible.  Next, 
harvest the femur/tibia by flushing the opening of the bone, which should 
be cut enough that it allows the passage of liquid, with L-cell or Bone 
Marrow-derived Macrophage growth media (courtesy Tall lab – Columbia 
University) into a falcon tube (approximately 2ml of liquid that should be 
cloudy with cells).  One leg (femur and tibia combined) should provide 
enough cells to seed 3 p100’s or 60 wells of a 12 well.  Cells should be 
plated in the special medias listed above as it encourages the cells to 
differentiate. 
The following three days (day 2-4) should be sent watching and 
waiting, allowing the cells to settle.  On day five, change the media and 
within a couple days macrophages should completely differentiate. 
Cholesterol Efflux from Bone Marrow Macrophages 
Cholesterol efflux from bone marrow derived macrophages was 
determined as follows.  Bone marrow macrophages, cultured as above, are 
incubated for 24hrs with 1-2 μCi/ml 3H cholesterol in minimal essential 
media (MEM) containing 10% fetal bovine serum in 12-well plates at 37°C 
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and 5% CO2.  After the incubation is complete, wash the cells 3 times in 
PBS and enrich the cells with cholesterol by incubation for 5 hours with 
acetylated LDL(BTI), 50 μg protein/ml, along with 1- 2 μCi/ml 3H 
cholesterol (GE) in minimal essential medium (MEM) containing 10% fetal 
bovine serum.  After the incubation, the medium is removed, the cells 
washed with phosphate-buffered saline (PBS) and then the cells are 
incubated with serum free MEM with either no acceptor, lipid free ApoA-I 
(10ug/ml) (BTI), or HDL (50ug/ml) (BTI).  Incubation with these different 
acceptors was done for various lengths of time (4, 8, 24hours).  Finally, the 
media is removed, centrifuged, and 100ul aliquots were counted in a 
scintillation counter. Additionally, the cells themselves were dissolved in 
0.1M NaOH for several hours and 100ul aliquots were counted. The 
percent efflux of lipid was calculated as cpm in medium divided by the sum 
of the cpm in the media and in the cells. Cholesterol efflux experiments 
were performed in triplicate, and the data (% efflux) are expressed as mean 
± std for 3-4 animals per genotype. 
Bisulfite Sequencing 
Bisulfite sequencing was carried out using the Qiagen Epitect 
Bisulfite Kit (Product # - 59104) by following the manufacturer’s 
instructions.  Briefly, prepare bisulfite mix as indicated.  Mix, 1 μg of DNA 
with 85μl of bisulfite mix, 35 μl DNA protect buffer and use RNase-free 
water to bring to 140 μl final volume.  Then put the reaction in a PCR 
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machine and run the following reaction.  Denaturation for 5 minutes at 
99°C, incubation for 25 minutes at 60°C, denaturation again for 5 minutes 
at 99°C, incubation again for 85 minutes at 60°C, denaturation a final time 
for 5 minutes at 99°C, incubation for 175 minutes at 60°C and finally hold 
for until ready at 20°C.  Afterwards, centrifuge the tubes, transfer the 
reaction to a new 1.5μl tube and add 560μl buffer BL.  Add the reaction to 
an epitect column and briefly spin so it sticks to the column.  Wash the 
column with 500 μl buffer BW.  Desulfonate the reaction with buffer BD 
(500μl), wash again with 500 μl buffer BW and then elute with 20 μl buffer 
EB. 
Chromatin Immunoprecipitation (ChIP) 
All ChIP procedures were done following the protocol provided with 
the Upstate Chip Kit (Catalog # 17-295).  Briefly, cells were grown to 1 x 
106 cells in a 10 cm dish.  Next, crosslink the cells by adding formaldehyde 
directly to the culture medium to a final concentration of 1% and incubate 
for 10 minutes at 37°C.  Aspirate off the medium and wash the cells twice 
with ice cold PBS containing protease inhibitors.  Scrape the cells into a 
conical tube.  Pellet the cells by spinning for 4 minutes at 200 RPM at 4°C.  
Resuspend the cells in 200 μl of warm SDS Lysis Buffer plus protease 
inhibitors and incubate on ice for 10 minutes.  Sonicate the lysate to shear 
DNA to length of 200-1000 bp’s.  Keep on ice during the sonication.  Add 
8μl 5M NACL and reverse crosslink at 65°C for 4hrs o/n.  Centrifuge the 
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samples for 10 minutes at 13,000 RPM at 4°C and transfer supernatant to a 
new tube.  Discard the pellet.  Dilute the supernatant 10x in ChIP Dilution 
Buffer plus protease inhibitors.  To reduce background, pre-clear the 2ml 
diluted supernatant with 75μl of Protein Agarose/Salmon Sperm DNA 
(50% slurry) for 30 minutes at 4°C with agitation.  Pellet agarose by brief 
centrifugation and collect supernatant. Add AB of choice to the 2ml 
fraction and incubate overnight at 4°C with rotation. The next day, add 60μl 
of Protein A Agarose/Salmon Sperm DNA (50% slurry) for one hour at 4°C 
with rotation.  Pellet agarose again with gentle centrifugation (700-1000 
RPM, 4°C, ~ 1 minute).  Wash the complex for 3-5 minutes on a rotating 
platform with 1ml of each of the following buffers on order, Low Salt 
Immune Complex Wash Buffer, High Salt Immune Complex Wash Buffer, 
LiCL Salt Immune Complex Wash Buffer, and 2X TE Buffer Salt Immune 
Complex Wash Buffer.  Elute cells in 250μl of fresh elution buffer (1% 
SDS, 0.1M NaHCO3), vortex gently and incubate at room temp for 15 
minutes with rotation.  Spin down agarose and carefully transfer the 
supernatant fraction to another tube and repeat elution.  Combine eluates 
(500μl). Add 20μl 5M NaCL to the eluate and reverse histone crosslink for 
4hrs at 65°C.  Add 10μl of 0.5 M EDTA, 20μl of 1M Tris-HCL, pH 6.5 and 
2μl of 10 mg/ml Proteinase K to the eluate and incubate for one hour at 
45°C.  Recover DNA with a phenol/chloroform extraction.   Use in PCR 
reaction. 
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AB’s Used - H3K9 dimethyl – Abcam catalog # ab1220, H3K27 trimethyl 
– Upstate catalog # 07-449, MBD2 – Upstate catalog # 07-198, H3K9 Anti 



















Chapter 5: Discussion and Future Direction 
 Discussion of StARD4   
The START domain-containing family of proteins have been shown 
to be involved in many pathways of intracellular lipid trafficking (Ponting 
and Aravind 1999; Strauss, Kishida et al. 2003; Prinz 2007).  It has been 
proposed that all proteins with a START domain, contain a similar binding 
pocket, that binds varying ligands or cholesterol derivatives based on 
modification of that binding domain (Iyer, Koonin et al. 2001).  StARD4 
belongs to the StARD4 subfamily, a START domain subfamily containing 
StARD4, StARD5 and StARD6.  StARD5 has previously been shown to 
bind cholesterol and 25-hydroxycholesterol while StARD4, StARD1 and 
MLN64 have been shown to only bind cholesterol (Rodriguez-Agudo, Ren 
et al. 2006; Rodriguez-Agudo, Ren et al. 2008).  Unlike StARD1 and 
MLN64, StARD4 and StARD5 do not have N-terminal localization 
sequences and are therefore predicted to be cytoplasmic proteins.   START 
domain cytoplasmic localization is not uncommon, exemplified by 
PCTP/StARD2, a protein that plays a crucial role in phosphatidyl choline 
intracellular transport (Feng, Chan et al. 2000; Kanno, Wu et al. 2007).  
Additionally, StARD4 and StARD5 share over 30% homology.  This thesis 
describes the first studies completed to directly examine the role of 
StARD4 in-vivo.  To this end, I created a StARD4 mouse knockout model 
to probe the physiological role of StARD4 in lipid metabolism.   
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Much to our surprise, mice homozygous for a mutation disrupting 
StARD4’s Start domain were healthy and displayed next to no 
abnormalities in plasma lipid dynamics, or in liver cholesterol metabolism.  
Dietary manipulations, as performed in this study, had no effect on overall 
lipid metabolism.  However, it can not be ruled out that a different dietary 
manipulation might be able to exacerbate the phenotype of the StARD4 
knockout.  Additionally, the time of exposure to a particular diet may also 
be of importance.  Finally, although candidate experimentation was done in 
areas related to lipid metabolism and atherosclerosis, other organ systems 
such as testis or adrenal glands, related to hormone production, might also 
serve as areas of investigation to uncover novel effects of StARD4. 
In total, six START family members have been knocked out in mice; 
StARD1, StARD2 (PCTP), StARD3 (MLN64), StARD11 (CERT) and 
StARD12 (DLC1 – deleted in liver cancer 1) and now StARD4.   StARD1 
knockout has provided a striking and clinically relevant phenotype as the 
knockout is the model used to study the human disease, congenital lipoid 
adrenal hyperplasia (Caron, Soo et al. 1998).  Both male and female 
StARD1 homozygous knockout mice have female external genitalia due to 
a generalized defect in steroid hormone biosynthesis.  Additionally, 
knockout mice die shortly after birth due to a generalized defect in steroid 
hormone production.  However, it has proven difficult to uncover and 
characterize lipid phenotypes in the other StAR protein mouse knockout 
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models.  Initial studies of PCTP disruption showed no difference in 
phospholipid metabolism, but did show increases in core body temperature 
and enlarged mitochondria in brown adipose tissue (van Helvoort, de 
Brouwer et al. 1999; Kang, Ribich et al. 2009).  However, when pushed 
with a lithogenic diet (15% fat, 1.225% cholesterol and 0.5% sodium 
cholate) known to form cholesterol gallstones, PCTP knockouts showed an 
impaired excretion of lipid into bile and an improper balance in the bile of 
cholesterol to phospholipids (Kanno, Wu et al. 2007; Scapa, Pocai et al. 
2008).  Mice with MLN64 mutations also have no apparent abnormalities 
in lipid metabolism or storage when pushed with a chow, high cholesterol 
or high fat diet (Kishida, Kostetskii et al. 2004).  StARD11 and StaRD12 
are both embryonic lethal.  StARD11 knockouts are embryonic lethal at day 
E11.5, caused by degeneration of the mitochondria (Wang, Rao et al. 
2009).  StARD12 knockouts are embryonic lethal at day E10.5 with defects 
in neural tube, brain, heart, placenta, actin filaments and focal adhesions 
(Durkin, Yuan et al. 2007).  StARD12 heterozygous mice are 
phenotypically normal.  This hints towards the level of complexity found 
between various START domain proteins that make a single mouse 
knockout model difficult to use for investigation of the START domain 
related proteins.    
In support of this idea, a family of proteins related to the StAR 
proteins, because their ligands are cholesterol dervitives or oxysterols is the 
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Oxysterol Binding Proteins (OSBP).  OSBPs are part of a large family of 
lipid binding proteins of which there are at least 12 members that play 
numerous roles in lipid distribution and metabolism (Prinz 2007).  A large 
amount of the work on ORPs (oxysterol related proteins) has been done in 
yeast S. cerevisiae, which has seven OSH (OSBP homolog) proteins all 
with a putative sterol binding pocket(Prinz 2007).  Yeast mutants for any 
one of the seven OSH genes have little to no defect in PM to ER sterol 
transfer suggesting a level of redundancy (Raychaudhuri, Im et al. 2006).  
However, conditional deletion of all seven genes slows exogenous sterol 
transport, causes vacuolar fragmentation and accumulation of lipid droplets 
ultimately ending in cell death (Beh, Cool et al. 2001; Beh and Rine 2004).   
Overall, there are many families of intracellular transporters, 
including, Niemann Pick C (NPC) proteins, the caveolins, OSBP and sterol 
carrier protein 2 (SCP-2) that all might play some role in compensating for 
the missing StARD4 protein.  A logical place to start would be to look at 
StARD5, a gene that as previously stated has 30% homology to the 
StARD4 protein.  StARD5 mouse knockouts were created in this laboratory 
by a previous graduate student Marc Waase, although the data remains 
unpublished.  Homozygous knockouts are embryonic lethal, much like 
StARD11 and StARD12.  The lethality happens before E3.5, indicative of 
an issue with fertilization, cleavage and compaction, making the embryos 
difficult to study.  Initial studies by Soccio et al. showed that StARD4 and 
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StARD5 are both capable of increasing cholesterol transport in-vitro, 
indicating a role for a compensatory mechanism between the two (Soccio 
and Breslow 2003).  It might therefore be interesting to cross the StARD4 
knockout with the StARD5 heterozygote.  However, it should also be noted 
that at least in liver, StARD5 appears to be expressed in Kuppfer cells, 
while StARD4 is expressed in parenchymal cells.   
Furthermore, it has even been suggested, that only a limited number 
of the genes involved in lipid transport and associated membrane 
trafficking have to date been identified (Chang, Chang et al. 2006).  Just 
recently, TMEM97 has been identified by an RNAi screen as a novel 
transporter binding to the NPC1 protein in the regulation of endosomal 
uptake of cholesterol from LDL particles (Bartz, Kern et al. 2009). 
It is important to emphasize that part of the construction of the 
knockout left room for the creation of tissue specific knockouts.  Although 
this thesis used a CMV-cre promoter to create a ubiquitous knockout, it is 
possible that tissue specific knockouts, perhaps a LysM-cre promoter for 
macrophage specific knockout, could be used to test for the role of StARD4 
as it relates to atherosclerosis.  The Tabas lab has shown successful use of 
gene specific knockouts to show increased apoptosis in mice with 
macrophage specific deletion of bcl2 (Thorp, Li et al. 2009).  Although in 
in-vitro bone marrow macrophage efflux assays, no significant differences 
were found in the rate of efflux of cholesterol to ApoA-I or HDL, it is 
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possible that StARD4, perhaps in combination with another protein, plays a 
role in the development of atherosclerosis by influencing macrophage 
cholesterol efflux. 
Interestingly, StARD4 mice seemed to have a weight related 
phenotype weighing about 2 grams less than wild-type littermate controls.   
It seemed that this was not due to issues involving food intake and the 
weight difference was not affected by a high fat diet.  This was suprising, 
but it is possible that some other metabolic change, perhaps alterations in 
resting thermodynamic state (a change in body heat), or in the rate of 
excersize of the animals can account for the weight changes. Additionally, 
the lengths of the animals were smaller, indicating that the size observation 
might be due to a more complicated metabolic defect of the StARD4 mice.   
It has been shown that non-steroidogenic COS-1 cells co-transfected with 
P450scc, 3β-hydroxysteroid reductase, necessary proteins for progesterone 
production, and StARD4 have mildly increased steroidogenesis (Soccio, 
Adams et al. 2005).  So, one could speculate that the absence of StARD4 
may impair steroid hormone production and compromise energy metabolics 
and growth (West and York 1998).  However, the decreased weight and 
length are in proportion with the mice overall being smaller, a phenotype 
that is very complex and could be related to any number of factors not 
discussed.   
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Another possible clue relating to the metabolic defect affecting 
StARD4 relates to the AKT signaling pathway.  Peripherally, the 
connection to Akt appears to be loose at best, although there is literature 
connecting Akt sequestration and signaling to lipid rafts; cholesterol rich 
scaffolding domains in the plasma membrane (Calay, Vind-Kezunovic et 
al.).  However, work done by one of the post docs in the laboratory, Jeanne 
Garbarino, has shown that a 60% ShRNA knockdown of StARD4 in 
HepG2 cells cultured in lipid deficient serum (LPDS) is capable of 
affecting Akt phosphorylation.  Specifically, of the two phosphorylation 
sites on Akt, serine 473 and threonine 308, StARD4 knockdown appears to 
decrease serine 473 activity.  Serine 473 phosphorylation is required for 
FoxO1 phosphorylation at threonine 24, which contributes to FoxO1 
inhibition via sequestration from the nucleus and increased lipogenesis.  As 
FoxO1 is a key regulator in modulating many energy metabolic functions, 
such as controlling insulin and gluconeogenic genes, it is possible to see a 
role for StARD4’s effects on Akt (Gross, Wan et al. 2009).  It would 
therefore make sense that downstream signaling targets of StARD4 could 
lead to abnormal development of the StARD4 mutant mouse.  Additionally, 
StARD4 knockdowns appear to have decreased endoplasmic reticulum 
cholesterol levels as found via subcellular fractionation as well as decreased 
cellular cholesterol ester and increased cellular triglycerides. 
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As support to this argument, Akt knockout mice, Akt1, Akt2 and 
Akt3 are all developmentally abnormal, albeit in different ways (Yang, 
Tschopp et al. 2004).  Akt1 mutant mice are small and have increased 
apoptosis in their thymus (Yang, Tschopp et al. 2003).   It was discovered, 
that Akt1 mutant mice had smaller placenta then their wild-type littermates, 
which deprived their embryos of normal nutrition during development and 
thus restricted animal growth.  Akt2 plays a different role, in that it helps 
regulate glucose metabolism, adipogenesis and maintenance, β-cell 
function and animal growth (Garofalo, Orena et al. 2003).  These mice also 
have severe diabetes and due to many complications suffer from age related 
loss of adipose tissue (lipoatrophy) and an overall decrease in size.  
Interesting to note, is that the Akt1/2 double knockout mice have severe 
growth retardation dying shortly after birth (Peng, Schwarz et al. 1997).   It 
was shown that this affect was probably due to skeletal muscle atrophy and 
abnormal bone development.  In contrast to Akt2 deficient mice, Akt3 
mutant mice do not exhibit increased perinatal mortalilty.   Rather, brain 
size and weight was reduced by 25%, attributed to a significant reduction in 
cell size and cell number (Yang, Tschopp et al. 2004).  
Peripherally, the connection to Akt appears to be loose at best, 
although there is literature connecting Akt sequestration and signaling to 
lipid rafts; cholesterol rich scaffolding domains in the plasma membrane 
(Calay, Vind-Kezunovic et al.).  However, work done by one of the post 
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doctoral fellowss in the laboratory, Jeanne Garbarino, has shown that a 
60% ShRNA knockdown of StARD4 in HepG2 cells cultured in lipid 
deficient serum (LPDS) is capable of effecting Akt phosphorylation.  
Specifically, of the two phosphorylation sites on Akt, serine 473 and 
threonine 308, StARD4 knockdown appears to decrease serine 473 activity.  
Serine 473 phosphorylation is required for FoxO1 phosphorylation at 
threonine 24, which contributes to FoxO1 inhibition via sequestration from 
the nucleus and increased lipogenesis.  As FoxO1 is a key regulator in 
modulating many energy metabolic functions, such as controlling insulin 
and gluconeogenic genes, it is possible to see a role for StARD4’s effects 
on Akt (Gross, Wan et al. 2009).  It would therefore make sense that 
downstream signaling targets of StARD4 could lead to abnormal 
development of the StARD4 mutant mouse.  Additionally, StARD4 
knockdowns appear to have decreased endoplasmic reticulum cholesterol 
levels as found via subcellular fractionation as well as decreased cellular 
cholesterol ester and increased cellular triglycerides. 
Female knockout mice showed a significant impairment of 
cholesterol and phospholipid excretion into gallbladder bile.   This is in 
agreement with previously published data that showed that over expression 
of StARD4 increased bile synthesis (Rodriguez-Agudo, Ren et al. 2008).  
As mentioned before, PCTP knockout mice also show an imbalance in 
cholesterol and phospholipids in the bile, indicating a complex mechanism 
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governing intracellular sterol dynamics.  This same study showed that 
StARD4 enhanced cholesterol ester synthesis in hepatocytes from 
exogenous cholesterol sources.   It is then tempting to postulate that the 
decrease in total cholesterol, LDL-C and cholesterol ester seen in females 
on the high cholesterol diet could somehow be mechanistically related to 
this earlier finding.  Perhaps StARD4 plays some role in shuttling between 
the ER and lipid droplets. 
Related to the bile phenotype found in female mice, it is known 
amongst physicians that females are more susceptible to gallstones, 
obstructive plaques in the gallbladder formed by the concentration of bile 
components (Kandutsch and Shown 1981).  The StARD4 knockout mice 
that exhibited changes in bile secretion were female and thus it is 
interesting to hypothesize whether this sex specific phenotype holds true 
between mice to humans.  It is known, that the primary pathophysiological 
defect in cholesterol gallstone disease (85% of cholelithiasis) is 
hypersecretion of hepatic cholesterol into bile with less frequent secretion 
of the two other components of bile, phospholipids and bile acids (Wang, 
Cohen et al. 2009).  There are other known secondary gallbladder 
dysfunctions that contribute to gallstones including hypomotility, immune 
mediated inflammation, accelerated phase transitions and hypersecretion of 
gelling mucins (Wang, Cohen et al. 2009).  StARD4 might thus be an 
attractive target for correcting the hypersecretion of hepatic cholesterol into 
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the bile.  It would certainly be of interest to the pharmaceutical industry as 
it is estimated that 20 million Americans are affected and that this number 
is only rising due to the spread of the obesity epidemic (NIDDK).  
Considering its role in cholesterol transport, it is possible that StARD4 
transports cholesterol to the ABCG5/8 transporters known to increase 
cholesterol gallbladder concentrations.  There are other alternative 
pathways for cholesterol to gain entry into gallbladder bile that would also 
need to be investigated.  Regardless, StARD4’s role in delivery of 
cholesterol to bile would underscore its importance in the reverse 
cholesterol transport pathway and might highlight its significance as a 
possible line of treatment against gallstone disease. 
It is possible that the major role of StARD4 is to transport newly 
synthesized cholesterol from the endoplasmic reticulum to its ultimate 
destination.  In previous experiments, I found that wild-type and StARD4 
knockout mouse macrophages pre-labeled with 3H-cholesterol did not 
differ in efflux of radiolabeled cholesterol to either ApoA-I or HDL.  To 
study whether or not StARD4 transports newly synthesized cholesterol 
from the endoplasmic reticulum, a similar experiment could be done except 
macrophages would be preincubated with labeled cholesterol precursors, 
14C-acetate or 14C-mevalonate.  In addition to efflux of newly synthesized 
radiolabeled cholesterol, the movement of labeled cholesterol from the 
endoplasmic reticulum to the plasma membrane and the esterification of 
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labeled cholesterol in the endoplasmic reticulum by the ACAT reaction 
could be quantified over time.   
Finally, it would be a good idea to start identifying binding partners 
of StARD4 in-vitro.  A mass spectrometry experiment could identify 
proteins purified and pulled down along with StARD4.  Does StARD4 
interact with NPC1 and move around endosomes?  Does it bind AKT and 
interact with lipid rafts in the plasma membrane?  It is important to realize 
that these experiments might prove challenging, as StARD4 is a cytosolic 
protein who interactions would likely be fleeting.  However, the 
information provided would give valuable clues about StARD4’s functional 
role.  The identity of its binding partners would help deduct where 
cholesterol actually docked, based on the localization of its binding 
partners; unless and this seems highly unlikely, it only bound other 
cytosolic proteins.  It would be possible to take this work one step further 
and conduct a fluorescence resonance energy transfer (FRET) experiment 
between StARD4 and some of its binding partners.  This would help to 
visualize the localization of the protein interactions in the cell.  As 
StARD4’s crystal structure has been solved, it might be possible once a 
binding partner is known, to reconstruct biochemically the transfer of 
cholesterol from a StARD4 molecule to its partner, which would be a 
significant breakthrough in the study of cholesterol protein transporters.  
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In conclusion, mutation of the START domain of StARD4, a protein 
thought to play a vital role in intracellular cholesterol dynamics and 
transport does not appear to impair cholesterol homeostasis intracellularly.  
These findings suggest that proteins with redundant functions exist that can 
supplement the role of StARD4 in-vivo and that the whole intracellular 
cholesterol milieu remains a complicated and under-developed research 

















Discussion of ApoA-I 
The importance of ApoA-I as a target for increasing HDL and 
reverse cholesterol transport and as a candidate for development of a novel 
therapeutic to help regulate a patient’s cholesterol levels was highlighted 
throughout the introductory section of this thesis.  It therefore remains of 
great interest to the research community to continue making headway into 
deciphering the various transcriptional machinery controlling ApoA-I.  The 
experiments done in the thesis highlighted the role methylation plays in 
facilitating transcription of ApoA-I and began to examine the ways histone 
marks effect transcription as well.  In the next section, I will propose some 
future steps that can be taken to continue this line of inquiry that would 
hopefully shed some light on the machinery controlling the ApoA-I gene.    
It would be logical to continue with the ChIP experiments to in order 
to determine the differential role either inhibitory mark (H3K27 tri-methyl 
or H3K9 tri-methyl) was playing in inhibiting ApoA-I.   As each of the two 
genes control very different pathways, much can be learned from 
differential markings on ApoA-I during inhibition.  H3K9 methylation by 
G9a, creates a binding platform for HP1 (α,β & γ) of which another protein 
DNMT1, a protein known to methylate stretches of genetic code, then 
binds, to control inhibition of certain genes (Smallwood, Esteve et al. 
2007).  It has been shown that a gene called Survivin can be inhibited by 
the recruitment of G9a, HP1 and DNMT1 alone, leading one to believe that 
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their might be a relatively simplified method for controlling gene repression 
(Smallwood, Esteve et al. 2007).  In contrast, H3K27 marks when 
trimethylated, are known to recruit Polycomb group proteins (PcG).  
Polycomb proteins form multimeric complexes that exert their functions by 
modifying chromatin structure and by regulating the disposition and 
recognition of multiple post-translational histone modifications 
(Schuettengruber, Chourrout et al. 2007).  It is therefore clear that 
distinguishing between these two types of marks, one relating to 
methylation, the other to histone modification, would be a major insight 
into the inhibitory state of ApoA-I.  Additional ChIPs of any of the 
downstream marks of H3K9 or H3K27, like HP1 or Polycomb, or any of 
the additional marks not included here, would help reconstruct the binding 
complex surrounding the ApoA-I promoter.  Once the marks associated 
with ApoA-I were established it would be interesting to do SiRNA 
knockdowns of any of these critical epigenetic and transcriptional marks 
and see in what set of combination or sequential order led to unlocking of 
the inhibitory marks and subsequent activation of the ApoA-I promoter. 
Also interesting, would be studies in-vitro to try and reconstitute a 
chromatin with histones, associated critical histone binding proteins and the 
ApoA-I DNA region to see if we could create ApoA-I message from our 
engineered complex.  Such studies have generated proof in the past for the 
necessity of certain transcription factors or chromatin remodeling events to 
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lead to the activation of a gene of interest.  For example, activation of the 
murine-mammary-tumor-virus (MMTV) by the glucocorticoid receptor was 
shown to be associated with a structural change in the B nucleosome region 
of the viral long term repeat (Hager, Fletcher et al. 2000).  This was proven 
by reconstituting nucleoprotein transition with chromatin assembled on 
MMTV long term repeat DNA with drosophila embryo extract, purified 
glucocorticoid receptor and HeLa cell nuclear extract.  This work was then 
shown in-vivo by using a tandem array of MMTV-Ras reporter element in 
living cells and a form of glucocorticoid receptor labeled with GFP, which 
allows for direct targeting to be observed.  
Some of these approaches would be extremely useful, in that they 
could be used to begin to map the kinetics of the interaction between 
ApoA-I’s transcription/chromatin factors.  Questions that could begin to be 
answered include:  Is the binding transient or long lasting?  How many 
factors are needed at one time to allow for transcription?  Are any of the 
factors altered during the process such that transcription is inactivated?  Are 
the remodeling events ATP dependent?  These types of studies would be of 
interest to the general research community, as increasing ApoA-I could lead 
to greater HDL production and ultimately more reverse cholesterol 
transport.  The hope of such experimention would be the creation of a novel 
therapeutic used to combat hypercholesteremia and ultimately decrease 
atherosclerosis and mortality in the world.   
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Finally, there are many small molecules that are being developed to 
enhance ApoA-I to treat atherosclerosis and Alzheimer’s disease.  An 
example is Resverlogix’s RVX-208 that has already been administered for 
28 days and 42 days in African green monkeys with ApoA-I levels 
increased 52% and HDL levels increased 75%, as compared to placebo.  To 
date the compound is starting Phase II clinical trials.  Given the nature of 
the development of small molecules, large library screens with the outcome 
predetermined and the mechanism of action not necessarily studied, 
understanding ApoA-I’s transcriptional machinery might help 
predict/prevent any unwanted side effects that might occur during a large 
Phase III clinical trials.  The benefit of this is clear and it underscores the 
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